modafinil has been researched along with Gelineau Syndrome in 179 studies
Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.
modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.
2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "gov; Names: Safety and Efficacy of Xyrem Oral Solution (Sodium Oxybate) Compared With Placebo in Narcoleptic Patients; Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy; URLs: https://clinicaltrials." | 9.34 | Incidence and duration of common, early-onset adverse events occurring during 2 randomized, placebo-controlled, phase 3 studies of sodium oxybate in participants with narcolepsy. ( Black, J; Bujanover, S; Husain, AM; Profant, J; Ryan, R; Scheckner, B, 2020) |
| "Effects of sodium oxybate (SXB) on patients with narcolepsy with cataplexy (NC) or without cataplexy (NWOC) have not been separately evaluated in clinical trials." | 9.22 | Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy. ( Black, J; Bogan, R; Carter, LP; Lai, C; Swick, T, 2016) |
| "This study was performed to evaluate the actions of baclofen and sodium oxybate, two medications with gamma-aminobutyric acid type B (GABA(B)) receptor agonist properties, on symptoms of narcolepsy in drug-naïve teenagers." | 9.14 | Narcolepsy: action of two gamma-aminobutyric acid type B agonists, baclofen and sodium oxybate. ( Guilleminault, C; Huang, YS, 2009) |
| "This double-blind, placebo-controlled study enrolled 278 patients with narcolepsy taking modafinil 200-600 mg daily for the treatment of excessive daytime sleepiness (EDS)." | 9.14 | The nightly administration of sodium oxybate results in significant reduction in the nocturnal sleep disruption of patients with narcolepsy. ( Black, J; Hornfeldt, CS; Inhaber, N; Pardi, D, 2009) |
| "This is the first report describing the efficacy of modafinil therapy for narcolepsy in patients in Taiwan." | 9.14 | Efficacy of modafinil in 10 Taiwanese patients with narcolepsy: findings using the Multiple Sleep Latency Test and Epworth Sleepiness Scale. ( Schenck, CH; Yeh, SB, 2010) |
| "To investigate the effect of modafinil on cortical excitability in patients with narcolepsy using transcranial magnetic stimulation (TMS)." | 9.14 | The effect of modafinil on cortical excitability in patients with narcolepsy: a randomized, placebo-controlled, crossover study. ( Hong, SB; Ji, KH; Joo, EY; Kim, HJ; Koo, DL; Lim, YH; Tae, WS, 2010) |
| "This 12-month, open-label, flexible-dose study with an extension period evaluated the tolerability and efficacy of armodafinil in patients with excessive sleepiness associated with treated obstructive sleep apnea (OSA), shift work disorder (SWD), or narcolepsy." | 9.14 | Tolerability and efficacy of armodafinil in naïve patients with excessive sleepiness associated with obstructive sleep apnea, shift work disorder, or narcolepsy: a 12-month, open-label, flexible-dose study with an extension period. ( Khan, A; McCall, WV; Schwartz, JR; Tiller, J; Weintraub, J, 2010) |
| "Patients with ES associated with treated OSA, SWD, or narcolepsy who completed one of four 12-week, double-blind studies were eligible for this multicenter, open-label study of > or = 12 months' duration of treatment with armodafinil (50 to 250 mg/day)." | 9.14 | The long-term tolerability and efficacy of armodafinil in patients with excessive sleepiness associated with treated obstructive sleep apnea, shift work disorder, or narcolepsy: an open-label extension study. ( Black, JE; Harsh, JR; Hull, SG; Tiller, J; Yang, R, 2010) |
| "This study indicates that modafinil is effective and well tolerated in the treatment of posttraumatic EDS but not of fatigue." | 9.14 | Modafinil ameliorates excessive daytime sleepiness after traumatic brain injury. ( Bassetti, CL; Baumann, CR; Kaiser, PR; Meier, J; Stocker, R; Thomann, J; Valko, PO; Werth, E, 2010) |
| " It is focused on the clinical and pharmacological properties of pitolisant in the treatment of narcolepsy." | 9.12 | Evaluating pitolisant as a narcolepsy treatment option. ( de Biase, S; Gigli, GL; Pellitteri, G; Valente, M, 2021) |
| "This study assessed the efficacy and safety of armodafinil, the longer half-life enantiomer of modafinil, for the treatment of excessive sleepiness in patients with narcolepsy." | 9.12 | The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. ( Arora, S; Harsh, JR; Hayduk, R; Niebler, GE; Rosenberg, R; Roth, T; Walsh, JK; Wesnes, KA, 2006) |
| "To assess the effectiveness of sodium oxybate therapy, modafinil therapy and the combination of the two for excessive daytime sleepiness in narcolepsy patients previously taking modafinil." | 9.12 | Sodium oxybate improves excessive daytime sleepiness in narcolepsy. ( Black, J; Houghton, WC, 2006) |
| "Low-resolution brain electromagnetic tomography (LORETA) showed a functional deterioration of the fronto-temporo-parietal network of the right hemispheric vigilance system in narcolepsy and a therapeutic effect of modafinil." | 9.12 | Low-resolution brain electromagnetic tomography (LORETA) identifies brain regions linked to psychometric performance under modafinil in narcolepsy. ( Anderer, P; Mandl, M; Saletu, B; Saletu, M; Saletu-Zyhlarz, GM; Semlitsch, HV; Zeitlhofer, J, 2007) |
| "To determine whether treatment with modafinil for excessive sleepiness improves fatigue, mood, and health-related quality of life (HRQOL) in patients with narcolepsy." | 9.11 | Effect of modafinil on fatigue, mood, and health-related quality of life in patients with narcolepsy. ( Becker, PM; Feldman, NT; Hughes, RJ; Schwartz, JR, 2004) |
| "To evaluate the hypothesis that visual P300 latency (VL) predicts treatment response to modafinil (a new wake-promoting agent) in patients with narcolepsy." | 9.09 | Visual P300 latency predicts treatment response to modafinil in patients with narcolepsy. ( Belisle, C; Sangal, JM; Sangal, RB, 1999) |
| "To evaluate the burden of illness of narcolepsy and assess the health-related quality-of-life (HQL) effects of oral modafinil, a wake-promoting therapy for excessive daytime sleepiness associated with narcolepsy." | 9.09 | Health-related quality of life effects of modafinil for treatment of narcolepsy. ( Beusterien, KM; Emsellem, HA; Goswami, M; Reblando, JA; Rogers, AE; Steinwald, B; Walsleben, JA; Wang, L, 1999) |
| "This is one of two separate clinical trials to evaluate the efficacy and safety of modafinil, a novel wake-promoting agent, in patients with excessive daytime sleepiness (EDS) associated with narcolepsy." | 9.09 | Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group. ( , 2000) |
| "Modafinil is a novel medication recently approved for the treatment of narcolepsy and idiopathic hypersomnia." | 9.09 | Problems associated with switch to modafinil - a novel alerting agent in narcolepsy. ( Aftab, FA; Guilleminault, C; Karadeniz, D; Leger, D; Philip, P, 2000) |
| "5 years) with narcolepsy-cataplexy were given modafinil (200 to 400 mg) at the Montpellier sleep disorders center from 1984 onwards." | 9.08 | Use of modafinil in the treatment of narcolepsy: a long term follow-up study. ( Besset, A; Billiard, M; Carlander, B; Chetrit, M, 1996) |
| "Modafinil (Provigil) is approved for treating excessive daytime sleepiness associated with narcolepsy, for shift-work sleep disorder, and as an adjunctive treatment in patients with obstructive sleep apnea syndrome who have residual daytime sleepiness despite optimal treatment with continuous positive airway pressure." | 8.84 | Modafinil in the treatment of excessive daytime sleepiness. ( Foldvary-Schaefer, N; Valentino, RM, 2007) |
| "Modafinil is a common treatment for excessive daytime sleepiness (EDS) in narcolepsy." | 8.31 | Pitolisant-supported bridging during drug holidays to deal with tolerance to modafinil in patients with narcolepsy. ( Apel, D; Ellwardt, E; Fleischer, V; Groppa, S; Kallweit, U; Lang, C; Winter, Y, 2023) |
| "We present behavioral and functional magnetic resonance imaging (fMRI) findings of a 20-year-old female with narcolepsy who completed a standardized fMRI-adapted face memory task both 'off' and 'on' modafinil compared to a normative sample (N = 38)." | 7.78 | Assessment of brain activity during memory encoding in a narcolepsy patient on and off modafinil using normative fMRI data. ( Allen, MD; Farrer, TJ; Hedges, DW; Larson, MJ, 2012) |
| "The benefit (Epworth sleepiness score, ESS; visual analog scale, patient and clinician opinions) and risks (habituation, adverse effects) of modafinil were studied in a consecutive clinical cohort of 104 IH patients (59 with long sleep time) and 126 patients with narcolepsy/cataplexy." | 7.77 | Benefit and risk of modafinil in idiopathic hypersomnia vs. narcolepsy with cataplexy. ( Arnulf, I; Dauvilliers, Y; Drouot, X; Franco, P; Golmard, JL; Lavault, S; Lecendreux, M; Leu-Semenescu, S, 2011) |
| "To investigate the effects of modafinil on regional cerebral blood flow (rCBF) in narcolepsy, we performed 99mTc-ethylcysteinate dimer single photon emission computed tomography (SPECT) before and after modafinil or placebo medication." | 7.74 | Effect of modafinil on cerebral blood flow in narcolepsy patients. ( Hong, SB; Joo, EY; Seo, DW; Tae, WS, 2008) |
| "Modafinil is an alerting agent approved for the treatment of narcolepsy in adults." | 7.72 | Modafinil in the treatment of excessive daytime sleepiness in children. ( Gozal, D; Ivanenko, A; Tauman, R, 2003) |
| "To explore whether acute destruction of hypocretin cells in a patient with narcolepsy could be detected and if the course of the disease could be reversed or altered by the use of prednisone for immunosuppression." | 7.72 | Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin-deficiency narcolepsy. ( Einen, M; Hecht, M; Kushida, CA; Lin, L; Mignot, E; Taheri, S; Umetsu, DT, 2003) |
| "This is a case report of a patient with narcolepsy treated simultaneously with modafinil and tranylcypromine." | 7.72 | Concomitant use of modafinil and tranylcypromine in a patient with narcolepsy: a case report. ( Clemons, WE; Makela, E; Young, J, 2004) |
| " Modafinil, a putative central alpha 1 adrenergic agonist, was tested in idiopathic hypersomnia and narcolepsy." | 7.67 | Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. ( Bastuji, H; Jouvet, M, 1988) |
| " Treatment lasted 8 weeks: 3 weeks of flexible dosing according to investigator's judgment (10 mg, 20 mg, or 40 mg a day of pitolisant; 100 mg, 200 mg or 400 mg a day of modafinil) followed by 5 weeks of stable dosing." | 6.78 | Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. ( Arnulf, I; Bassetti, C; Dauvilliers, Y; Ding, CL; Lammers, GJ; Lecomte, JM; Lehert, P; Mayer, G; Rodenbeck, A; Schwartz, JC, 2013) |
| " All modafinil dosing regimens were well tolerated." | 6.71 | Dose effects of modafinil in sustaining wakefulness in narcolepsy patients with residual evening sleepiness. ( Bogan, RK; Feldman, NT; Schwartz, JR, 2005) |
| "Modafinil is a pharmacologically and clinically promising compound for the treatment of pathological daytime somnolence." | 6.69 | Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group. ( , 1998) |
| " Both compounds induced potent wake-promoting effects in littermate wild-type and orexin-tTA; TetO-DTA mice when dosed at active and resting phases." | 5.91 | Comparison of Solriamfetol and Modafinil on Arousal and Anxiety-Related Behaviors in Narcoleptic Mice. ( Nishino, S; Sakai, N, 2023) |
| "Modafinil was later used to treat sleepiness, somnolence and fatigue in a large number of medical conditions." | 5.48 | Modafinil: its discovery, the early European and North American experience in the treatment of narcolepsy and idiopathic hypersomnia, and its subsequent use in other medical conditions. ( Billiard, M; Broughton, R, 2018) |
| "gov; Names: Safety and Efficacy of Xyrem Oral Solution (Sodium Oxybate) Compared With Placebo in Narcoleptic Patients; Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy; URLs: https://clinicaltrials." | 5.34 | Incidence and duration of common, early-onset adverse events occurring during 2 randomized, placebo-controlled, phase 3 studies of sodium oxybate in participants with narcolepsy. ( Black, J; Bujanover, S; Husain, AM; Profant, J; Ryan, R; Scheckner, B, 2020) |
| "Effects of sodium oxybate (SXB) on patients with narcolepsy with cataplexy (NC) or without cataplexy (NWOC) have not been separately evaluated in clinical trials." | 5.22 | Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy. ( Black, J; Bogan, R; Carter, LP; Lai, C; Swick, T, 2016) |
| "Modafinil improves driving performance in patients with narcolepsy and idiopathic hypersomnia." | 5.19 | Modafinil improves real driving performance in patients with hypersomnia: a randomized double-blind placebo-controlled crossover clinical trial. ( Capelli, A; Chaufton, C; Coste, O; Léger, D; Moore, N; Philip, P; Sagaspe, P; Taillard, J, 2014) |
| "This study was performed to evaluate the actions of baclofen and sodium oxybate, two medications with gamma-aminobutyric acid type B (GABA(B)) receptor agonist properties, on symptoms of narcolepsy in drug-naïve teenagers." | 5.14 | Narcolepsy: action of two gamma-aminobutyric acid type B agonists, baclofen and sodium oxybate. ( Guilleminault, C; Huang, YS, 2009) |
| "This double-blind, placebo-controlled study enrolled 278 patients with narcolepsy taking modafinil 200-600 mg daily for the treatment of excessive daytime sleepiness (EDS)." | 5.14 | The nightly administration of sodium oxybate results in significant reduction in the nocturnal sleep disruption of patients with narcolepsy. ( Black, J; Hornfeldt, CS; Inhaber, N; Pardi, D, 2009) |
| "Sodium oxybate (SXB) is an approved drug for the treatment of excessive daytime sleepiness (EDS) and cataplexy in narcolepsy." | 5.14 | A safety trial of sodium oxybate in patients with obstructive sleep apnea: Acute effects on sleep-disordered breathing. ( Feldman, N; George, CF; Grzeschik, SM; Inhaber, N; Lai, C; Steininger, TL; Zheng, Y, 2010) |
| "Prospective evaluation of unselected traumatic brain injury patients with nocturnal polysomnography (NPSG), multiple sleep latency test (MSLT), Epworth Sleepiness Scale (ESS), and neuropsychological testing including Psychomotor Vigilance Test (PVT), Profile of Mood States (POMS), and Functional Outcome of Sleep Questionnaire (FOSQ) before and after treatment with continuous positive airway pressure (CPAP) for obstructive sleep apnea (OSA), modafinil (200 mg) for narcolepsy and posttraumatic hypersomnia (PTH), or pramipexole (0." | 5.14 | Treatment of sleep disorders after traumatic brain injury. ( Atanasov, S; Castriotta, RJ; Kuna, ST; Lai, JM; Masel, BE; Wilde, MC, 2009) |
| "This is the first report describing the efficacy of modafinil therapy for narcolepsy in patients in Taiwan." | 5.14 | Efficacy of modafinil in 10 Taiwanese patients with narcolepsy: findings using the Multiple Sleep Latency Test and Epworth Sleepiness Scale. ( Schenck, CH; Yeh, SB, 2010) |
| "As previously reported, motor threshold and SICI were significantly increased in patients with narcolepsy; modafinil reversed this cortical hypoexcitability, but only SICI differences reached statistical significance." | 5.14 | Modafinil reverses hypoexcitability of the motor cortex in narcoleptic patients: a TMS study. ( Bergmann, J; Caleri, F; Golaszewski, S; Kunz, A; Ladurner, G; Lochner, P; Nardone, R; Staffen, W; Tezzon, F; Trinka, E, 2010) |
| "To investigate the effect of modafinil on cortical excitability in patients with narcolepsy using transcranial magnetic stimulation (TMS)." | 5.14 | The effect of modafinil on cortical excitability in patients with narcolepsy: a randomized, placebo-controlled, crossover study. ( Hong, SB; Ji, KH; Joo, EY; Kim, HJ; Koo, DL; Lim, YH; Tae, WS, 2010) |
| "This 12-month, open-label, flexible-dose study with an extension period evaluated the tolerability and efficacy of armodafinil in patients with excessive sleepiness associated with treated obstructive sleep apnea (OSA), shift work disorder (SWD), or narcolepsy." | 5.14 | Tolerability and efficacy of armodafinil in naïve patients with excessive sleepiness associated with obstructive sleep apnea, shift work disorder, or narcolepsy: a 12-month, open-label, flexible-dose study with an extension period. ( Khan, A; McCall, WV; Schwartz, JR; Tiller, J; Weintraub, J, 2010) |
| "Patients with ES associated with treated OSA, SWD, or narcolepsy who completed one of four 12-week, double-blind studies were eligible for this multicenter, open-label study of > or = 12 months' duration of treatment with armodafinil (50 to 250 mg/day)." | 5.14 | The long-term tolerability and efficacy of armodafinil in patients with excessive sleepiness associated with treated obstructive sleep apnea, shift work disorder, or narcolepsy: an open-label extension study. ( Black, JE; Harsh, JR; Hull, SG; Tiller, J; Yang, R, 2010) |
| "This study indicates that modafinil is effective and well tolerated in the treatment of posttraumatic EDS but not of fatigue." | 5.14 | Modafinil ameliorates excessive daytime sleepiness after traumatic brain injury. ( Bassetti, CL; Baumann, CR; Kaiser, PR; Meier, J; Stocker, R; Thomann, J; Valko, PO; Werth, E, 2010) |
| "We recommend that clinicians use modafinil for the treatment of narcolepsy in adults." | 5.12 | Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. ( Hashmi, SD; Kotagal, S; Maski, K; Robert Auger, R; Rowley, JA; Trotti, LM; Watson, NF, 2021) |
| " It is focused on the clinical and pharmacological properties of pitolisant in the treatment of narcolepsy." | 5.12 | Evaluating pitolisant as a narcolepsy treatment option. ( de Biase, S; Gigli, GL; Pellitteri, G; Valente, M, 2021) |
| "This study assessed the efficacy and safety of armodafinil, the longer half-life enantiomer of modafinil, for the treatment of excessive sleepiness in patients with narcolepsy." | 5.12 | The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. ( Arora, S; Harsh, JR; Hayduk, R; Niebler, GE; Rosenberg, R; Roth, T; Walsh, JK; Wesnes, KA, 2006) |
| "To assess the effectiveness of sodium oxybate therapy, modafinil therapy and the combination of the two for excessive daytime sleepiness in narcolepsy patients previously taking modafinil." | 5.12 | Sodium oxybate improves excessive daytime sleepiness in narcolepsy. ( Black, J; Houghton, WC, 2006) |
| "Low-resolution brain electromagnetic tomography (LORETA) showed a functional deterioration of the fronto-temporo-parietal network of the right hemispheric vigilance system in narcolepsy and a therapeutic effect of modafinil." | 5.12 | Low-resolution brain electromagnetic tomography (LORETA) identifies brain regions linked to psychometric performance under modafinil in narcolepsy. ( Anderer, P; Mandl, M; Saletu, B; Saletu, M; Saletu-Zyhlarz, GM; Semlitsch, HV; Zeitlhofer, J, 2007) |
| "To determine whether treatment with modafinil for excessive sleepiness improves fatigue, mood, and health-related quality of life (HRQOL) in patients with narcolepsy." | 5.11 | Effect of modafinil on fatigue, mood, and health-related quality of life in patients with narcolepsy. ( Becker, PM; Feldman, NT; Hughes, RJ; Schwartz, JR, 2004) |
| "Patients ( n=40) with excessive daytime sleepiness related to narcolepsy, who had received previous treatment with methylphenidate, were switched from methylphenidate to modafinil (200 mg/day followed by 400 mg/day) without a washout period between treatments, with a 2-day washout period between treatments, or by using a taper-down/titrate-up protocol." | 5.10 | Initiating treatment with modafinil for control of excessive daytime sleepiness in patients switching from methylphenidate: an open-label safety study assessing three strategies. ( Hayduk, R; Kovacevic-Ristanovic, R; Schwartz, JR; Thorpy, MJ, 2003) |
| "Patients (N=151) with narcolepsy who had been unsatisfactorily treated with dextroamphetamine (N=48), methylphenidate (N=66), or pemoline (N=37) were enrolled in this 6-week, open-label, multicenter study." | 5.10 | Efficacy and safety of modafinil for improving daytime wakefulness in patients treated previously with psychostimulants. ( Feldman, NT; Fry, JM; Harsh, J; Schwartz, JR, 2003) |
| "To evaluate the hypothesis that visual P300 latency (VL) predicts treatment response to modafinil (a new wake-promoting agent) in patients with narcolepsy." | 5.09 | Visual P300 latency predicts treatment response to modafinil in patients with narcolepsy. ( Belisle, C; Sangal, JM; Sangal, RB, 1999) |
| "To evaluate the burden of illness of narcolepsy and assess the health-related quality-of-life (HQL) effects of oral modafinil, a wake-promoting therapy for excessive daytime sleepiness associated with narcolepsy." | 5.09 | Health-related quality of life effects of modafinil for treatment of narcolepsy. ( Beusterien, KM; Emsellem, HA; Goswami, M; Reblando, JA; Rogers, AE; Steinwald, B; Walsleben, JA; Wang, L, 1999) |
| "This is one of two separate clinical trials to evaluate the efficacy and safety of modafinil, a novel wake-promoting agent, in patients with excessive daytime sleepiness (EDS) associated with narcolepsy." | 5.09 | Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group. ( , 2000) |
| "Modafinil is a novel medication recently approved for the treatment of narcolepsy and idiopathic hypersomnia." | 5.09 | Problems associated with switch to modafinil - a novel alerting agent in narcolepsy. ( Aftab, FA; Guilleminault, C; Karadeniz, D; Leger, D; Philip, P, 2000) |
| "5 years) with narcolepsy-cataplexy were given modafinil (200 to 400 mg) at the Montpellier sleep disorders center from 1984 onwards." | 5.08 | Use of modafinil in the treatment of narcolepsy: a long term follow-up study. ( Besset, A; Billiard, M; Carlander, B; Chetrit, M, 1996) |
| "Modafinil is an alerting substance which has been used successfully to treat narcolepsy." | 5.08 | Effect of modafinil on plasma melatonin, cortisol and growth hormone rhythms, rectal temperature and performance in healthy subjects during a 36 h sleep deprivation. ( Bastuji, H; Boissy, I; Brun, J; Chamba, G; Claustrat, B; Girard, P; Khalfallah, Y; Sassolas, G, 1998) |
| "Modafinil (200-400 mg/d), sodium oxybate 9 g/d, and pitolisant up to 40 mg/d had similar efficacy in reducing excessive day time sleepiness." | 4.98 | Multiple treatment comparison in narcolepsy: a network meta-analysis. ( Falissard, B; Lehert, P, 2018) |
| "Modafinil is a synthetic molecule used for the treatment of narcolepsy." | 4.93 | A Critical Review of Properties of Modafinil and Analytical, Bioanalytical Methods for its Determination. ( Ramachandra, B, 2016) |
| "For more than two decades psychiatrists have known about and have promoted modafinil, a very promising stimulant that boosts wakefulness in cases of narcolepsy and also enhances cognitive functions." | 4.86 | [Modafinil in psychiatric disorders: the promising state reconsidered]. ( Docx, L; Dom, G; Joos, L; Sabbe, BG; Schmaal, L, 2010) |
| " Narcolepsy, which is characterized by daytime sleepiness and irresistible episodes of sleep, is treated by an alpha1 noradrenergic stimulant modafinil which has no amphetaminic properties." | 4.84 | [Sleep and wakefulness drugs and their indications]. ( Bourin, M, 2007) |
| "Modafinil (Provigil) is approved for treating excessive daytime sleepiness associated with narcolepsy, for shift-work sleep disorder, and as an adjunctive treatment in patients with obstructive sleep apnea syndrome who have residual daytime sleepiness despite optimal treatment with continuous positive airway pressure." | 4.84 | Modafinil in the treatment of excessive daytime sleepiness. ( Foldvary-Schaefer, N; Valentino, RM, 2007) |
| "The majority of recent papers in this field provide information about use of modafinil or sodium oxybate for treatment of sleepiness associated with narcolepsy." | 4.84 | Treatment of narcolepsy and other hypersomnias of central origin. ( Arand, DL; Auger, RR; Brooks, SN; Watson, NF; Wise, MS, 2007) |
| "Armodafinil is a wake-promoting agent developed by Cephalon that was approved in mid-2007 for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea and shift work disorder." | 4.84 | Armodafinil: a new treatment for excessive sleepiness. ( Lankford, DA, 2008) |
| "The participant was a 30-year-old primipara with narcolepsy, taking modafinil (300 mg morning, 100 mg noon) while breastfeeding her 6-week-old infant despite the paucity of safety information." | 4.31 | Infant Exposure to Armodafinil Through Human Milk Following Maternal Use of Modafinil. ( Costi, L; Elliot, D; Hague, WM; Leggett, C; Mangoni, AA; Ritchie, U, 2023) |
| "Modafinil is a common treatment for excessive daytime sleepiness (EDS) in narcolepsy." | 4.31 | Pitolisant-supported bridging during drug holidays to deal with tolerance to modafinil in patients with narcolepsy. ( Apel, D; Ellwardt, E; Fleischer, V; Groppa, S; Kallweit, U; Lang, C; Winter, Y, 2023) |
| "The wake-promoting drug Modafinil has been used for treatment of sleep disorders, such as Narcolepsy, excessive daytime sleepiness and sleep apnea, due to its stimulant action." | 3.88 | Increased interferon-mediated immunity following in vitro and in vivo Modafinil treatment on peripheral immune cells. ( Andersen, ML; Brandão, WN; Cruz, DSG; Kornum, BR; Margatho, RO; Moresco, M; Palermo-Neto, J; Peron, JP; Pizza, F; Plazzi, G; Tufik, S; Zager, A, 2018) |
| " He was most interested first in patients with disorders of consciousness and secondly in those with sleep/wake disorders, and especially in modafinil for the treatment of patients with narcolepsy and idiopathic hypersomnia." | 3.88 | Michel Jouvet as a clinical neurophysiologist and neurologist. ( Bastuji, H, 2018) |
| " Withdrawal of the narcolepsy treatment and initiation of haloperidol 1 mg/day (the only antipsychotic treatment she could tolerate) improved the delusions, hallucinations and dysphoria but worsened the narcolepsy symptoms." | 3.85 | Narcolepsy-cataplexy and psychosis: a case study. ( Arango-Lopez, C; Canellas-Dols, F; Delgado, C; Peraita-Adrados, R, 2017) |
| "Current treatment recommendations for narcolepsy suggest that modafinil should be used as a first-line treatment ahead of conventional stimulants or sodium oxybate." | 3.83 | Sleep-stage sequencing of sleep-onset REM periods in MSLT predicts treatment response in patients with narcolepsy. ( Drakatos, P; Kent, BD; Leschziner, GD; Patel, K; Thakrar, C; Williams, AJ, 2016) |
| "Modafinil is a non-amphetaminic wake-promoting compound used as therapy against sleepiness and narcolepsy." | 3.83 | Impact of Astroglial Connexins on Modafinil Pharmacological Properties. ( Charvériat, M; Chauveau, F; Dauvilliers, Y; Duchêne, A; Giaume, C; Jeanson, T; Lagarde, D; Lin, JS; Liu, X; Mouthon, F; Perier, M; Picoli, C; Piérard, C; Thomasson, J; Zhao, Y, 2016) |
| "Long-term modafinil therapy may ameliorate the sleep disturbances of Prader-Willi syndrome and should be the focus of future clinical trials." | 3.80 | Prader-Willi syndrome, excessive daytime sleepiness, and narcoleptic symptoms: a case report. ( Couch, R; Foulds, JL; Haqq, AM; Rubin, D; Weselake, SV; Witmans, MB, 2014) |
| "Modafinil (Provigil) was marketed in the UK in 1998 to promote wakefulness in the treatment of narcolepsy." | 3.79 | Safety profile of modafinil across a range of prescribing indications, including off-label use, in a primary care setting in England: results of a modified prescription-event monitoring study. ( Davies, M; Shakir, S; Wilton, L, 2013) |
| "We present behavioral and functional magnetic resonance imaging (fMRI) findings of a 20-year-old female with narcolepsy who completed a standardized fMRI-adapted face memory task both 'off' and 'on' modafinil compared to a normative sample (N = 38)." | 3.78 | Assessment of brain activity during memory encoding in a narcolepsy patient on and off modafinil using normative fMRI data. ( Allen, MD; Farrer, TJ; Hedges, DW; Larson, MJ, 2012) |
| "We report the case of a 22-year-old male who exhibited severe manic behavior shortly after beginning treatment with modafinil and venlafaxine for narcolepsy with cataplexy." | 3.77 | Severe mania complicating treatment of narcolepsy with cataplexy. ( Bradshaw, DA; Crosby, MI; McLay, RN, 2011) |
| "The benefit (Epworth sleepiness score, ESS; visual analog scale, patient and clinician opinions) and risks (habituation, adverse effects) of modafinil were studied in a consecutive clinical cohort of 104 IH patients (59 with long sleep time) and 126 patients with narcolepsy/cataplexy." | 3.77 | Benefit and risk of modafinil in idiopathic hypersomnia vs. narcolepsy with cataplexy. ( Arnulf, I; Dauvilliers, Y; Drouot, X; Franco, P; Golmard, JL; Lavault, S; Lecendreux, M; Leu-Semenescu, S, 2011) |
| "We evaluated the wake-promoting efficacy of paraxanthine, caffeine, and a reference wake-promoting compound, modafinil, in a mice model of narcolepsy, a prototypical disease model of hypersomnia." | 3.76 | Effects of paraxanthine and caffeine on sleep, locomotor activity, and body temperature in orexin/ataxin-3 transgenic narcoleptic mice. ( Fujiki, N; Ishimaru, Y; Kotorii, N; Nishino, S; Okuro, M; Sokoloff, P, 2010) |
| "To investigate the effects of modafinil on regional cerebral blood flow (rCBF) in narcolepsy, we performed 99mTc-ethylcysteinate dimer single photon emission computed tomography (SPECT) before and after modafinil or placebo medication." | 3.74 | Effect of modafinil on cerebral blood flow in narcolepsy patients. ( Hong, SB; Joo, EY; Seo, DW; Tae, WS, 2008) |
| " Modafinil is a novel non-addicting psychostimulant approved for treatment of narcolepsy." | 3.73 | Modafinil in sports: ethical considerations. ( Kaufman, KR, 2005) |
| "Modafinil is an alerting agent approved for the treatment of narcolepsy in adults." | 3.72 | Modafinil in the treatment of excessive daytime sleepiness in children. ( Gozal, D; Ivanenko, A; Tauman, R, 2003) |
| "To explore whether acute destruction of hypocretin cells in a patient with narcolepsy could be detected and if the course of the disease could be reversed or altered by the use of prednisone for immunosuppression." | 3.72 | Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin-deficiency narcolepsy. ( Einen, M; Hecht, M; Kushida, CA; Lin, L; Mignot, E; Taheri, S; Umetsu, DT, 2003) |
| "This is a case report of a patient with narcolepsy treated simultaneously with modafinil and tranylcypromine." | 3.72 | Concomitant use of modafinil and tranylcypromine in a patient with narcolepsy: a case report. ( Clemons, WE; Makela, E; Young, J, 2004) |
| "Cross-sectional survey with data obtained from the clinical trials assessing the safety and efficacy of modafinil in the treatment of narcolepsy." | 3.72 | The month-of-birth pattern in narcolepsy is moderated by cataplexy severity and may be independent of HLA-DQB1*0602. ( Harsh, JR; Mignot, EJ; Picchioni, D, 2004) |
| " Modafinil, a putative central alpha 1 adrenergic agonist, was tested in idiopathic hypersomnia and narcolepsy." | 3.67 | Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. ( Bastuji, H; Jouvet, M, 1988) |
| "Modafinil, which was approved for idiopathic hypersomnia until 2011 in Europe, is the most commonly used treatment and improved sleepiness in two recent randomized placebo-controlled trials." | 3.01 | Update on the treatment of idiopathic hypersomnia: Progress, challenges, and expert opinion. ( Arnulf, I; Dauvilliers, Y; Roy, A; Thomas, R, 2023) |
| "Idiopathic hypersomnia (IH) includes a clinical phenotype resembling narcolepsy (with repeated, short restorative naps), and a phenotype with an excess of sleep, sleep drunkenness, drowsiness, and infrequent long, nonrestorative naps." | 2.82 | Precision Medicine for Idiopathic Hypersomnia. ( Arnulf, I; Dodet, P; Leu-Semenescu, S, 2022) |
| " Treatment lasted 8 weeks: 3 weeks of flexible dosing according to investigator's judgment (10 mg, 20 mg, or 40 mg a day of pitolisant; 100 mg, 200 mg or 400 mg a day of modafinil) followed by 5 weeks of stable dosing." | 2.78 | Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. ( Arnulf, I; Bassetti, C; Dauvilliers, Y; Ding, CL; Lammers, GJ; Lecomte, JM; Lehert, P; Mayer, G; Rodenbeck, A; Schwartz, JC, 2013) |
| "Narcolepsy is characterized by excessive daytime sleepiness (EDS), cataplexy, direct onsets of rapid eye movement (REM) sleep from wakefulness (DREMs) and deficiency of orexins, neuropeptides that promote wakefulness largely via activation of histamine (HA) pathways." | 2.73 | An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients. ( Anaclet, C; Arnulf, I; Bastuji, H; Dauvilliers, Y; Kocher, L; Lecomte, JM; Lehert, P; Ligneau, X; Lin, JS; Parmentier, R; Perrin, D; Robert, P; Roux, M; Schwartz, JC; Yanagisawa, M, 2008) |
| "Narcolepsy is a rare, chronic, and disabling central nervous system hypersomnia; two forms can be recognized: narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2)." | 2.72 | A practical guide to the pharmacological and behavioral therapy of Narcolepsy. ( Cavalli, F; Franceschini, C; Pizza, F; Plazzi, G, 2021) |
| "Narcolepsy is an uncommon hypothalamic disorder of presumed autoimmune origin that usually requires lifelong treatment." | 2.72 | European guideline and expert statements on the management of narcolepsy in adults and children. ( Baldin, E; Bassetti, CLA; Dauvilliers, Y; Dolenc-Groselj, L; Jennum, P; Kallweit, U; Khatami, R; Lammers, GJ; Lecendreux, M; Manconi, M; Mayer, G; Partinen, M; Plazzi, G; Pollmächer, T; Reading, P; Santamaria, J; Sonka, K; Vignatelli, L, 2021) |
| "Narcolepsy is an uncommon hypothalamic disorder of presumed autoimmune origin that usually requires lifelong treatment." | 2.72 | European guideline and expert statements on the management of narcolepsy in adults and children. ( Baldin, E; Bassetti, CLA; Dauvilliers, Y; Dolenc-Groselj, L; Jennum, P; Kallweit, U; Khatami, R; Lammers, GJ; Lecendreux, M; Manconi, M; Mayer, G; Partinen, M; Plazzi, G; Pollmächer, T; Reading, P; Santamaria, J; Sonka, K; Vignatelli, L, 2021) |
| " All modafinil dosing regimens were well tolerated." | 2.71 | Dose effects of modafinil in sustaining wakefulness in narcolepsy patients with residual evening sleepiness. ( Bogan, RK; Feldman, NT; Schwartz, JR, 2005) |
| "Modafinil is a pharmacologically and clinically promising compound for the treatment of pathological daytime somnolence." | 2.69 | Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group. ( , 1998) |
| "Modafinil caused an increase in self-reported levels of alertness in 7 of 8 narcoleptic subjects, but there was no significant difference between mean pretreatment and post-treatment activation levels as determined by fMRI for either normal or narcoleptic syndrome subjects given modafinil." | 2.69 | Functional magnetic resonance imaging neuroactivation studies in normal subjects and subjects with the narcoleptic syndrome. Actions of modafinil. ( Brammer, M; Bullmore, E; Ellis, CM; Lemmens, G; Monk, C; Parkes, JD; Simmons, A; Williams, SC, 1999) |
| "Narcolepsy is a sleep disorder associated with HLA DR15 (DR2) and DQB1*0602." | 2.68 | HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. ( Black, J; Grumet, FC; Guilleminault, C; Hayduk, R; Mignot, E, 1997) |
| "Modafinil is a nonamphetamine nootropic drug with an increasingly therapeutic interest due to its different sites of action and behavioral effects in comparison to cocaine or amphetamine." | 2.66 | Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects. ( Dinis-Oliveira, RJ; Sousa, A, 2020) |
| "Excessive daytime sleepiness (EDS) is related to medical and social problems, including mental disorders, physical diseases, poor quality of life, and so forth." | 2.66 | Pharmacologic Management of Excessive Daytime Sleepiness. ( Nishino, S; Takenoshita, S, 2020) |
| "Narcolepsy is an orphan neurological disease and presents with sleep-wake, motoric, neuropsychiatric and metabolic symptoms." | 2.55 | Pharmacological management of narcolepsy with and without cataplexy. ( Bassetti, CL; Kallweit, U, 2017) |
| "Narcolepsy is a chronic sleep disorder that has a typical onset in adolescence and is characterized by excessive daytime sleepiness, which can have severe consequences for the patient." | 2.55 | Narcolepsy. ( Dauvilliers, Y; Jennum, PJ; Knudsen, S; Kornum, BR; Ollila, HM; Overeem, S; Pizza, F, 2017) |
| "Until now, the treatment of idiopathic hypersomnia has mirrored that of the sleepiness of narcolepsy type 1 or 2." | 2.53 | Idiopathic hypersomnia. ( Billiard, M; Sonka, K, 2016) |
| "Narcolepsy is an emblematic, unique disease within sleep disorders that is characterised by excessive daytime sleepiness, cataplexy and other abnormal manifestations of REM sleep." | 2.48 | [Diagnostic and therapeutic update in narcolepsy]. ( Santamaria-Cano, J, 2012) |
| "Narcolepsy is a neurodegenerative disorder resulting in the instability of the sleep-wake cycle and marked by low levels of hypocretin in cerebrospinal fluid." | 2.46 | Expert opinion on pharmacotherapy of narcolepsy. ( Dimitriu, A; Guilleminault, C; Zaharna, M, 2010) |
| "Narcolepsy is a serious neurological condition in which patients are overcome by persistent, excessive feelings of fatigue and drowsiness." | 2.45 | Narcolepsy: clinical decision making for the primary care physician. ( Hazin, R; Iqbal, M; Khan, F, 2009) |
| "Clinical trials in these sleep disorders demonstrated an enhanced efficacy for wake promotion (wake sustained for a longer time period using doses lower than those of modafinil)." | 2.44 | Armodafinil for excessive daytime sleepiness. ( Nishino, S; Okuro, M, 2008) |
| "Narcolepsy was found to cause some of the highest measures of excessive sleepiness." | 2.44 | Stay awake! Understanding, diagnosing, and successfully managing narcolepsy. ( Doghramji, PP; Gordon, ML; Lieberman, JA, 2007) |
| "Modafinil is a wake-promoting agent that is pharmacologically different from other stimulants." | 2.44 | Approved and investigational uses of modafinil : an evidence-based review. ( Kumar, R, 2008) |
| "Cataplexy is managed by medications whereas behavioral treatment, such as avoidance of emotion, was the only treatment available in the past." | 2.44 | Therapeutic advances in narcolepsy. ( Thorpy, M, 2007) |
| "Successful treatment of hypersomnia of central origin requires an accurate diagnosis, individual tailoring of therapy to produce the fullest possible return of normal function, and regular follow-up to monitor response to treatment." | 2.44 | Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. ( Alessi, C; Aurora, RN; Boehlecke, B; Brown, T; Chesson, AL; Friedman, L; Kapur, VK; Maganti, R; Morgenthaler, TI; Owens, J; Pancer, J; Swick, TJ; Zak, R, 2007) |
| "Narcolepsy is a disabling disease with a prevalence of 0." | 2.44 | Pediatric narcolepsy. ( Husain, AM; Peterson, PC, 2008) |
| "Excessive daytime somnolence is a prevalent problem in medical practice and in society." | 2.43 | Conditions of primary excessive daytime sleepiness. ( Black, JE; Brooks, SN; Nishino, S, 2005) |
| "Narcolepsy is a neurological disorder characterized by excessive daytime sleepiness and cataplexy." | 2.43 | Molecular genetics and treatment of narcolepsy. ( Dauvilliers, Y; Tafti, M, 2006) |
| "Modafinil is a unique wake-promoting agent for oral administration." | 2.42 | Clinical pharmacokinetic profile of modafinil. ( Hellriegel, ET; Robertson, P, 2003) |
| "Modafinil has a safer side-effect profile and as a result, interest in this drug for the management of EDS in other disorders, as well as narcolepsy, has increased considerably." | 2.42 | Pharmacotherapy for excessive daytime sleepiness. ( Banerjee, D; Grunstein, RR; Vitiello, MV, 2004) |
| "Modafinil may increase wakefulness through activation of noradrenergic and dopaminergic systems, possibly through interaction with the hypocretin/orexin system." | 2.42 | What keeps us awake: the neuropharmacology of stimulants and wakefulness-promoting medications. ( Boutrel, B; Koob, GF, 2004) |
| " Both compounds induced potent wake-promoting effects in littermate wild-type and orexin-tTA; TetO-DTA mice when dosed at active and resting phases." | 1.91 | Comparison of Solriamfetol and Modafinil on Arousal and Anxiety-Related Behaviors in Narcoleptic Mice. ( Nishino, S; Sakai, N, 2023) |
| "Central disorders of hypersomnolence include narcolepsy type 1, narcolepsy type 2, idiopathic hypersomnia and hypersomnia associated with medical or mental disorders." | 1.91 | [Potential teratogenicity of modafinil - Conflicting evidence, need for research]. ( Arnulf, I; Beghin, D; Coulm, B; Dauvilliers, Y; Elefant, E; Latour, M; Marin, B; Vauzelle, C, 2023) |
| "A 67-year-old woman with neuromyelitis optica spectrum disorder (NMOSD) developed severe somnolence." | 1.56 | Somnolence Preceded the Development of a Subthalamic Lesion in Neuromyelitis Optica Spectrum Disorder. ( Ando, M; Daida, K; Hattori, N; Hayashida, A; Kanbayashi, T; Noda, K; Ogaki, K; Okuma, Y; Yokoyama, K, 2020) |
| "Narcolepsy is a life-long neurological disorder characterized by excessive daytime sleepiness (EDS) and cataplexy." | 1.51 | Antidepressants for the treatment of narcolepsy: A prospective study of 148 patients in northern China. ( Chen, BB; Jin, L; Liu, YH; Shi, L; Wang, XL; Zhang, Y, 2019) |
| "Patients with narcolepsy with cataplexy reported 59 pregnancies versus 164 in the control group." | 1.48 | Narcolepsy with cataplexy and pregnancy: a case-control study. ( Calvo-Ferrandiz, E; Peraita-Adrados, R, 2018) |
| "Modafinil was the most common drug used as a first-line treatment (93%) and in combination therapy (70%)." | 1.48 | Effectiveness and side-effect profile of stimulant therapy as monotherapy and in combination in the central hypersomnias in clinical practice. ( D'ancona, G; Drakatos, P; Kent, BD; Leschziner, GD; Nesbitt, A; Patel, K; Rosenzweig, I; Selsick, H; Steier, J; Thakrar, C; Williams, AJ, 2018) |
| "Modafinil was later used to treat sleepiness, somnolence and fatigue in a large number of medical conditions." | 1.48 | Modafinil: its discovery, the early European and North American experience in the treatment of narcolepsy and idiopathic hypersomnia, and its subsequent use in other medical conditions. ( Billiard, M; Broughton, R, 2018) |
| "Narcolepsy type 1 and focal epilepsy was diagnosed." | 1.48 | The Comorbidity of Focal Epilepsy and Narcolepsy Type 1 - Two Case Reports. ( Klobucnikova, K; Kollar, B; Muchova, I; Siarnik, P; Štofko, J, 2018) |
| "Cataplexy is by far the most predictive feature of narcolepsy." | 1.40 | Status cataplecticus as initial presentation of late onset narcolepsy. ( Panda, S, 2014) |
| "Narcolepsy is characterised by excessive daytime sleepiness and cataplexy and has a prevalence of 25 per 100,000." | 1.36 | National narcolepsy survey. ( Crowe, C; Doherty, L; Sweeney, B, 2010) |
| "Modafinil was reported to be effective for treating sleepiness, venlafaxine for cataplexy, and sodium oxybate for all symptoms, across all puberty groups." | 1.36 | Clinical and therapeutic aspects of childhood narcolepsy-cataplexy: a retrospective study of 51 children. ( Aran, A; Einen, M; Lin, L; Mignot, E; Nishino, S; Plazzi, G, 2010) |
| "Modafinil is a unique drug and has potential for many interactions with anaesthetic agents; these are discussed in this report." | 1.35 | Day case general anaesthesia in a patient with narcolepsy. ( Doyle, A; Wilkinson, D, 2008) |
| " These agents can increase wakefulness (W) in cats and rodents following acute administration, but their effects after repeat dosing have not been reported previously." | 1.35 | Differential effects of acute and repeat dosing with the H3 antagonist GSK189254 on the sleep-wake cycle and narcoleptic episodes in Ox-/- mice. ( Anaclet, C; Brown, SH; Buda, C; Feng, JQ; Franco, P; Guidon, G; Guo, RX; Lin, JS; Medhurst, AD; Parmentier, R; Roberts, JC; Sastre, JP; Upton, N; Zhang, M, 2009) |
| "Narcolepsy is a neurological disorder affecting the regulation of sleep and wakefulness." | 1.35 | Narcolepsy--master of disguise: evidence-based recommendations for management. ( Mohsenin, V, 2009) |
| "Narcolepsy is characterized by symptoms that include excessive sleepiness during the daytime, cataplexy, hypnagogic hallucinations and sleep paralysis." | 1.35 | Narcolepsy and psychotic states--a case report. ( Daliahu, Y; Melamed, Y; Paleacu, D, 2009) |
| "For treating cataplexy, the most widely used medications include the antidepressants venlafaxine, imipramine, and protriptyline, usually at lower doses than prescribed with depression, and sodium oxybate." | 1.34 | Narcolepsy: treatment issues. ( Roth, T, 2007) |
| "Modafinil, that is an effective treatment of hypersomnia, did not alleviate the symptoms of fibrositis in the short term." | 1.29 | Fibrositis syndrome and narcolepsy. ( Bernard, PM; Disdier, P; Genton, P; Milandre, C; Millet, Y, 1993) |
| "In contrast, the results of cataplexy testing demonstrate that amphetamine (2." | 1.29 | Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs. ( Dement, WC; Mignot, E; Nishino, S; Shelton, J; Vaught, J, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.56) | 18.7374 |
| 1990's | 24 (13.41) | 18.2507 |
| 2000's | 80 (44.69) | 29.6817 |
| 2010's | 54 (30.17) | 24.3611 |
| 2020's | 20 (11.17) | 2.80 |
| Authors | Studies |
|---|---|
| Gauffin, H | 1 |
| Fast, T | 1 |
| Komkova, A | 1 |
| Berntsson, S | 1 |
| Boström, I | 1 |
| Landtblom, AM | 1 |
| Maski, K | 1 |
| Trotti, LM | 1 |
| Kotagal, S | 1 |
| Robert Auger, R | 1 |
| Rowley, JA | 1 |
| Hashmi, SD | 1 |
| Watson, NF | 2 |
| Arnulf, I | 9 |
| Leu-Semenescu, S | 2 |
| Dodet, P | 1 |
| Leggett, C | 3 |
| Ritchie, U | 3 |
| Costi, L | 3 |
| Elliot, D | 3 |
| Mangoni, AA | 3 |
| Hague, WM | 3 |
| Sakai, N | 2 |
| Nishino, S | 11 |
| Marin, B | 1 |
| Latour, M | 1 |
| Vauzelle, C | 1 |
| Coulm, B | 1 |
| Beghin, D | 1 |
| Dauvilliers, Y | 17 |
| Elefant, E | 1 |
| Thomas, R | 1 |
| Roy, A | 1 |
| Winter, Y | 1 |
| Lang, C | 1 |
| Kallweit, U | 4 |
| Apel, D | 1 |
| Fleischer, V | 1 |
| Ellwardt, E | 1 |
| Groppa, S | 1 |
| Daida, K | 1 |
| Ogaki, K | 1 |
| Hayashida, A | 1 |
| Ando, M | 1 |
| Yokoyama, K | 1 |
| Noda, K | 1 |
| Kanbayashi, T | 1 |
| Hattori, N | 1 |
| Okuma, Y | 1 |
| Sousa, A | 1 |
| Dinis-Oliveira, RJ | 1 |
| Thorpy, MJ | 3 |
| Bogan, RK | 2 |
| Husain, AM | 2 |
| Bujanover, S | 1 |
| Ryan, R | 1 |
| Scheckner, B | 1 |
| Black, J | 6 |
| Profant, J | 1 |
| Takenoshita, S | 1 |
| de Biase, S | 1 |
| Pellitteri, G | 1 |
| Gigli, GL | 1 |
| Valente, M | 1 |
| Kaplan, S | 1 |
| Braverman, DL | 1 |
| Frishman, I | 1 |
| Bartov, N | 1 |
| Franceschini, C | 1 |
| Pizza, F | 3 |
| Cavalli, F | 1 |
| Plazzi, G | 8 |
| Sivam, S | 1 |
| Chamula, K | 1 |
| Swieca, J | 1 |
| Frenkel, S | 1 |
| Saini, B | 1 |
| Bassetti, CLA | 2 |
| Vignatelli, L | 2 |
| Lecendreux, M | 5 |
| Baldin, E | 2 |
| Dolenc-Groselj, L | 3 |
| Jennum, P | 2 |
| Khatami, R | 2 |
| Manconi, M | 2 |
| Mayer, G | 8 |
| Partinen, M | 3 |
| Pollmächer, T | 3 |
| Reading, P | 3 |
| Santamaria, J | 2 |
| Sonka, K | 4 |
| Lammers, GJ | 5 |
| Krief, S | 1 |
| Berrebi-Bertrand, I | 1 |
| Nagmar, I | 1 |
| Giret, M | 1 |
| Belliard, S | 1 |
| Perrin, D | 2 |
| Uguen, M | 1 |
| Robert, P | 2 |
| Lecomte, JM | 3 |
| Schwartz, JC | 3 |
| Finance, O | 1 |
| Ligneau, X | 2 |
| Bassetti, CL | 3 |
| Calvo-Ferrandiz, E | 1 |
| Peraita-Adrados, R | 3 |
| Canellas-Dols, F | 1 |
| Delgado, C | 1 |
| Arango-Lopez, C | 1 |
| Zager, A | 1 |
| Brandão, WN | 1 |
| Margatho, RO | 1 |
| Cruz, DSG | 1 |
| Peron, JP | 1 |
| Tufik, S | 1 |
| Andersen, ML | 1 |
| Moresco, M | 1 |
| Kornum, BR | 2 |
| Palermo-Neto, J | 1 |
| Thakrar, C | 2 |
| Patel, K | 2 |
| D'ancona, G | 1 |
| Kent, BD | 2 |
| Nesbitt, A | 1 |
| Selsick, H | 1 |
| Steier, J | 1 |
| Rosenzweig, I | 1 |
| Williams, AJ | 3 |
| Leschziner, GD | 2 |
| Drakatos, P | 2 |
| Roth, T | 3 |
| Guinta, D | 1 |
| Alvarez-Horine, S | 1 |
| Dynin, E | 1 |
| Bastuji, H | 5 |
| Lin, JS | 4 |
| Roussel, B | 1 |
| Gaspar, A | 1 |
| Zhao, Y | 2 |
| Hou, Y | 1 |
| Schmidt, M | 1 |
| Jouvet, A | 1 |
| Jouvet, M | 2 |
| Billiard, M | 7 |
| Broughton, R | 1 |
| Klobucnikova, K | 1 |
| Siarnik, P | 1 |
| Muchova, I | 1 |
| Štofko, J | 1 |
| Kollar, B | 1 |
| Lehert, P | 4 |
| Falissard, B | 1 |
| Szabo, ST | 1 |
| Peever, JH | 1 |
| Kilduff, TS | 1 |
| Sagaspe, P | 2 |
| Micoulaud-Franchi, JA | 1 |
| Coste, O | 2 |
| Léger, D | 3 |
| Espié, S | 1 |
| Davenne, D | 1 |
| Lopez, R | 2 |
| Philip, P | 3 |
| Jin, L | 1 |
| Shi, L | 1 |
| Zhang, Y | 1 |
| Chen, BB | 1 |
| Wang, XL | 1 |
| Liu, YH | 1 |
| Davies, M | 1 |
| Wilton, L | 1 |
| Shakir, S | 1 |
| Strambi, LF | 1 |
| Bassetti, C | 2 |
| Rodenbeck, A | 1 |
| Ding, CL | 2 |
| Panda, S | 1 |
| Chaufton, C | 1 |
| Taillard, J | 1 |
| Capelli, A | 1 |
| Moore, N | 1 |
| Weselake, SV | 1 |
| Foulds, JL | 1 |
| Couch, R | 1 |
| Witmans, MB | 1 |
| Rubin, D | 1 |
| Haqq, AM | 1 |
| van der Heide, A | 1 |
| van Schie, MK | 1 |
| van Dijk, JG | 1 |
| Lavault, S | 2 |
| Inocente, CO | 1 |
| Konofal, E | 2 |
| Cortese, S | 1 |
| Franco, P | 4 |
| Ramachandra, B | 1 |
| Duchêne, A | 1 |
| Perier, M | 1 |
| Liu, X | 1 |
| Thomasson, J | 1 |
| Chauveau, F | 1 |
| Piérard, C | 1 |
| Lagarde, D | 1 |
| Picoli, C | 1 |
| Jeanson, T | 1 |
| Mouthon, F | 1 |
| Giaume, C | 1 |
| Charvériat, M | 1 |
| Sagawa, Y | 1 |
| Sato, M | 1 |
| Chikahisa, S | 1 |
| Chiba, S | 1 |
| Maruyama, T | 1 |
| Yamamoto, J | 1 |
| Swick, T | 1 |
| Bogan, R | 1 |
| Lai, C | 2 |
| Carter, LP | 1 |
| Knudsen, S | 1 |
| Ollila, HM | 1 |
| Jennum, PJ | 1 |
| Overeem, S | 1 |
| Doyle, A | 1 |
| Wilkinson, D | 1 |
| Joo, EY | 3 |
| Seo, DW | 1 |
| Tae, WS | 3 |
| Hong, SB | 3 |
| Okuro, M | 2 |
| Doghramji, PP | 1 |
| Lieberman, JA | 1 |
| Gordon, ML | 1 |
| Kumar, R | 1 |
| Wu, P | 1 |
| Jones, S | 1 |
| Ryan, CJ | 1 |
| Michail, D | 1 |
| Robinson, TD | 1 |
| Siegel, JM | 1 |
| Hoque, R | 1 |
| Chesson, AL | 2 |
| Hegerl, U | 1 |
| Guerrero, IL | 1 |
| Sander, C | 1 |
| Akins, BE | 1 |
| Miranda, E | 1 |
| Lacy, JM | 1 |
| Logan, BK | 1 |
| Paquereau, J | 1 |
| Drouot, X | 2 |
| Weil, JS | 1 |
| Viot-Blanc, V | 1 |
| Saletu, M | 3 |
| Anderer, P | 4 |
| Saletu-Zyhlarz, GM | 4 |
| Mandl, M | 4 |
| Saletu, B | 4 |
| Zeitlhofer, J | 4 |
| Guo, RX | 1 |
| Anaclet, C | 2 |
| Roberts, JC | 1 |
| Parmentier, R | 2 |
| Zhang, M | 1 |
| Guidon, G | 1 |
| Buda, C | 1 |
| Sastre, JP | 1 |
| Feng, JQ | 1 |
| Brown, SH | 1 |
| Upton, N | 1 |
| Medhurst, AD | 1 |
| Fujiki, N | 2 |
| Cheng, T | 1 |
| Yoshino, F | 1 |
| Mohsenin, V | 1 |
| Huang, YS | 1 |
| Guilleminault, C | 5 |
| Yasui-Furukori, N | 1 |
| Kusunoki, M | 1 |
| Kaneko, S | 1 |
| Pardi, D | 1 |
| Hornfeldt, CS | 1 |
| Inhaber, N | 2 |
| Garnock-Jones, KP | 1 |
| Dhillon, S | 1 |
| Scott, LJ | 1 |
| Dang-Vu, TT | 1 |
| Desseilles, M | 1 |
| Schwartz, S | 1 |
| Maquet, P | 1 |
| Melamed, Y | 1 |
| Daliahu, Y | 1 |
| Paleacu, D | 1 |
| George, CF | 2 |
| Feldman, N | 1 |
| Steininger, TL | 1 |
| Grzeschik, SM | 1 |
| Zheng, Y | 1 |
| Castriotta, RJ | 1 |
| Atanasov, S | 1 |
| Wilde, MC | 1 |
| Masel, BE | 1 |
| Lai, JM | 1 |
| Kuna, ST | 1 |
| Khan, F | 1 |
| Hazin, R | 1 |
| Iqbal, M | 1 |
| Rossetti, AO | 1 |
| Heinzer, RC | 1 |
| Tafti, M | 4 |
| Buclin, T | 1 |
| Tarrant, N | 1 |
| Cavanna, AE | 1 |
| Rickards, H | 1 |
| Zaharna, M | 1 |
| Dimitriu, A | 1 |
| Doherty, L | 1 |
| Crowe, C | 1 |
| Sweeney, B | 1 |
| Kotorii, N | 1 |
| Ishimaru, Y | 1 |
| Sokoloff, P | 1 |
| Golicki, D | 1 |
| Bala, MM | 1 |
| Niewada, M | 1 |
| Wierzbicka, A | 1 |
| Yeh, SB | 1 |
| Schenck, CH | 1 |
| Nardone, R | 1 |
| Bergmann, J | 1 |
| Lochner, P | 1 |
| Caleri, F | 1 |
| Kunz, A | 1 |
| Staffen, W | 1 |
| Tezzon, F | 1 |
| Ladurner, G | 1 |
| Trinka, E | 1 |
| Golaszewski, S | 1 |
| Kim, HJ | 1 |
| Lim, YH | 1 |
| Koo, DL | 1 |
| Ji, KH | 1 |
| Soltanifar, S | 1 |
| Russell, R | 1 |
| Schwartz, JR | 5 |
| Khan, A | 1 |
| McCall, WV | 1 |
| Weintraub, J | 1 |
| Tiller, J | 2 |
| Black, JE | 2 |
| Hull, SG | 1 |
| Yang, R | 1 |
| Harsh, JR | 3 |
| Joos, L | 1 |
| Docx, L | 1 |
| Schmaal, L | 1 |
| Sabbe, BG | 1 |
| Dom, G | 1 |
| Kaiser, PR | 1 |
| Valko, PO | 1 |
| Werth, E | 1 |
| Thomann, J | 1 |
| Meier, J | 1 |
| Stocker, R | 1 |
| Baumann, CR | 1 |
| Aran, A | 1 |
| Einen, M | 2 |
| Lin, L | 3 |
| Mignot, E | 8 |
| Raggi, A | 1 |
| Pennisi, G | 1 |
| Tasca, D | 1 |
| Ferri, R | 1 |
| Morimoto, Y | 1 |
| Nogami, Y | 1 |
| Harada, K | 1 |
| Shiramoto, H | 1 |
| Moguchi, T | 1 |
| Crosby, MI | 1 |
| Bradshaw, DA | 1 |
| McLay, RN | 1 |
| Golmard, JL | 1 |
| Quinnell, TG | 1 |
| Smith, IE | 1 |
| Allen, MD | 1 |
| Hedges, DW | 1 |
| Farrer, TJ | 1 |
| Larson, MJ | 1 |
| Bruni, O | 1 |
| Gringras, P | 1 |
| Nevsimalova, S | 1 |
| Paiva, T | 1 |
| Peeters, E | 1 |
| Poli, F | 1 |
| Santamaria-Cano, J | 1 |
| Patnaik, SK | 1 |
| Raju, U | 1 |
| Garg, A | 1 |
| Robertson, P | 1 |
| Hellriegel, ET | 1 |
| Robb-Nicholson, C | 1 |
| Kovacevic-Ristanovic, R | 1 |
| Hayduk, R | 3 |
| Poza, JJ | 1 |
| Ault, A | 1 |
| Feldman, NT | 3 |
| Fry, JM | 1 |
| Harsh, J | 1 |
| Ivanenko, A | 1 |
| Tauman, R | 1 |
| Gozal, D | 1 |
| Becker, PM | 1 |
| Hughes, RJ | 1 |
| Hecht, M | 1 |
| Kushida, CA | 1 |
| Umetsu, DT | 1 |
| Taheri, S | 1 |
| Banerjee, D | 1 |
| Vitiello, MV | 1 |
| Grunstein, RR | 1 |
| Clemons, WE | 1 |
| Makela, E | 1 |
| Young, J | 1 |
| Boutrel, B | 1 |
| Koob, GF | 1 |
| Saletu, MT | 1 |
| Arnold, O | 2 |
| Nosiska, D | 1 |
| Willie, JT | 2 |
| Renthal, W | 1 |
| Chemelli, RM | 2 |
| Miller, MS | 1 |
| Scammell, TE | 1 |
| Yanagisawa, M | 3 |
| Sinton, CM | 2 |
| Cormican, LJ | 1 |
| Picchioni, D | 1 |
| Mignot, EJ | 1 |
| Kaufman, KR | 1 |
| Miller, MC | 1 |
| Vorspan, F | 1 |
| Warot, D | 1 |
| Consoli, A | 1 |
| Cohen, D | 1 |
| Mazet, P | 1 |
| Wisor, JP | 2 |
| Eriksson, KS | 1 |
| Giles, J | 1 |
| Brooks, SN | 2 |
| Rosenberg, R | 1 |
| Wesnes, KA | 1 |
| Walsh, JK | 1 |
| Arora, S | 1 |
| Niebler, GE | 1 |
| Parmeggiani, A | 1 |
| Scano, MC | 1 |
| Posar, A | 1 |
| Bernardi, F | 1 |
| Lodi, R | 1 |
| Tonon, C | 1 |
| Barbiroli, B | 1 |
| Montagna, P | 1 |
| Cicognani, A | 1 |
| Houghton, WC | 1 |
| Semlitsch, HV | 1 |
| Janeiro, M | 1 |
| Camblor, E | 1 |
| Fernández, R | 1 |
| Núñez, D | 1 |
| Thorpy, M | 1 |
| Kim, YK | 1 |
| Yoon, IY | 1 |
| Shin, YK | 1 |
| Cho, SS | 1 |
| Kim, SE | 1 |
| Bourin, M | 1 |
| Valentino, RM | 1 |
| Foldvary-Schaefer, N | 1 |
| Morgenthaler, TI | 1 |
| Kapur, VK | 1 |
| Brown, T | 1 |
| Swick, TJ | 1 |
| Alessi, C | 1 |
| Aurora, RN | 1 |
| Boehlecke, B | 1 |
| Friedman, L | 1 |
| Maganti, R | 1 |
| Owens, J | 1 |
| Pancer, J | 1 |
| Zak, R | 1 |
| Wise, MS | 1 |
| Arand, DL | 1 |
| Auger, RR | 1 |
| Jung, KY | 1 |
| Kocher, L | 1 |
| Roux, M | 1 |
| Lankford, DA | 1 |
| Peterson, PC | 1 |
| Laffont, F | 2 |
| Agar, N | 1 |
| Minz, M | 2 |
| Dement, WC | 2 |
| Boivin, DB | 1 |
| Montplaisir, J | 1 |
| Petit, D | 1 |
| Lambert, C | 1 |
| Lubin, S | 1 |
| Besset, A | 2 |
| Villemin, E | 1 |
| Disdier, P | 1 |
| Genton, P | 1 |
| Milandre, C | 1 |
| Bernard, PM | 1 |
| Millet, Y | 1 |
| Chetrit, M | 1 |
| Carlander, B | 1 |
| Shelton, J | 1 |
| Vaught, J | 1 |
| Lamberg, L | 1 |
| Le Cacheux, P | 1 |
| Charasse, C | 1 |
| Mourtada, R | 1 |
| Muh, P | 1 |
| Boulahrouz, R | 1 |
| Simon, P | 1 |
| Broughton, RJ | 1 |
| Fleming, JA | 1 |
| Hill, JD | 1 |
| Kryger, MH | 1 |
| Moldofsky, H | 1 |
| Montplaisir, JY | 1 |
| Morehouse, RL | 1 |
| Moscovitch, A | 1 |
| Murphy, WF | 1 |
| Ferraro, L | 1 |
| Antonelli, T | 1 |
| O'Connor, WT | 1 |
| Tanganelli, S | 1 |
| Rambert, FA | 1 |
| Fuxe, K | 1 |
| Grumet, FC | 1 |
| Brun, J | 1 |
| Chamba, G | 1 |
| Khalfallah, Y | 1 |
| Girard, P | 1 |
| Boissy, I | 1 |
| Sassolas, G | 1 |
| Claustrat, B | 1 |
| Mitler, MM | 2 |
| Walsleben, J | 1 |
| Sangal, RB | 2 |
| Hirshkowitz, M | 1 |
| Ellis, CM | 1 |
| Monk, C | 1 |
| Simmons, A | 1 |
| Lemmens, G | 1 |
| Williams, SC | 2 |
| Brammer, M | 1 |
| Bullmore, E | 1 |
| Parkes, JD | 1 |
| Sangal, JM | 1 |
| Belisle, C | 1 |
| Jefferson, HJ | 1 |
| Jayne, DR | 1 |
| Elmquist, JK | 1 |
| Scammell, T | 1 |
| Lee, C | 1 |
| Richardson, JA | 1 |
| Xiong, Y | 1 |
| Kisanuki, Y | 1 |
| Fitch, TE | 1 |
| Nakazato, M | 1 |
| Hammer, RE | 1 |
| Saper, CB | 1 |
| Beusterien, KM | 1 |
| Rogers, AE | 1 |
| Walsleben, JA | 1 |
| Emsellem, HA | 1 |
| Reblando, JA | 1 |
| Wang, L | 1 |
| Goswami, M | 1 |
| Steinwald, B | 1 |
| Miller, JL | 1 |
| Derenne, JP | 1 |
| Aftab, FA | 1 |
| Karadeniz, D | 1 |
| Hauser, RA | 1 |
| Wahba, MN | 1 |
| Zesiewicz, TA | 1 |
| McDowell Anderson, W | 1 |
| Sora, I | 1 |
| Uhl, GH | 1 |
| Edgar, DM | 1 |
| Teitelman, E | 1 |
| Gorman, C | 1 |
| Narendran, R | 1 |
| Young, CM | 1 |
| Valenti, AM | 1 |
| Nickolova, MK | 1 |
| Pristach, CA | 1 |
| Neidhart, E | 1 |
| Marcus, CL | 1 |
| Trescher, WH | 1 |
| Halbower, AC | 1 |
| Lutz, J | 1 |
| Hajdukovic, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial Comparing the Effects of Orally Administered Xyrem (Sodium Oxybate) With Placebo for the Treatment of Narcolepsy[NCT00049803] | Phase 3 | 200 participants | Interventional | 2000-12-31 | Completed | ||
| Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multi-Center Trial Comparing the Effects of Orally Administered Xyrem (Sodium Oxybate) and Modafinil With Placebo in Treatment of Daytime Sleepiness in Narcolepsy[NCT00066170] | Phase 3 | 231 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients[NCT05319093] | 40 participants (Anticipated) | Observational | 2022-04-30 | Not yet recruiting | |||
| Prospective, Randomized, Double-blind Study, Placebo-controlled, Parallel-group, Multi-center Trial Assessing the Effects of BF2.649 in Treatment of Excessive Daytime Sleepiness in Narcolepsy[NCT01067222] | Phase 3 | 110 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Therapeutic Impact of THN102 on Attention, Wakefulness and Cognitive Performance During Total Sleep Deprivation in Healthy Subjects[NCT03182413] | Phase 1 | 20 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Improvement in Sleep Symptomatology and Neurocognitive Function Using Photobiomodulation in Post-Concussion Patients With Sleep-Wake Disturbances[NCT05072743] | 20 participants (Anticipated) | Interventional | 2021-10-20 | Recruiting | |||
| Treating Comorbid Depression of Patients With Narcolepsy by Intermittent Theta Burst Stimulation: A Preliminary Study[NCT05884112] | 105 participants (Anticipated) | Interventional | 2023-02-22 | Recruiting | |||
| Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies, Impact of Modafinil Treatment.[NCT00916253] | 27 participants (Actual) | Interventional | 2010-03-31 | Completed | |||
| The Effect of Caffeine on the Narcoleptic Patients Randomized Controlled Clinical Trial[NCT02832336] | Phase 1/Phase 2 | 16 participants (Actual) | Interventional | 2016-10-01 | Completed | ||
| A Randomized, Double Blind, Placebo Controlled Evaluation of Modafinil vs Placebo for the Treatment of General Anesthesia Related Delayed Emergence in Patients With the Diagnosis of Obstructive Sleep Apnea[NCT02494102] | Phase 4 | 105 participants (Actual) | Interventional | 2016-02-29 | Terminated | ||
| Modafinil Treatment for Sleep/Wake Disturbances in Older Adults[NCT00626210] | Phase 4 | 2 participants (Actual) | Interventional | 2008-02-29 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Maintenance of Wakefulness Test consisted of four 20 minute tests of the patient's ability to remain awake in soporific conditions. The Mean change from baseline to week 8 in the average MWT number of minutes until sleep onset was the primary endpoint. (NCT00066170)
Timeframe: Baseline to Week 8
| Intervention | Minutes (Mean) |
|---|---|
| Xyrem Placebo + Modafinil Placebo | -2.72 |
| Xyrem + Modafinil Placebo | 0.58 |
| Xyrem Placebo + Modafinil at Established Dose | -0.53 |
| Xyrem + Modafinil at Established Dose | 2.68 |
Length of time of above compared between groups (NCT02494102)
Timeframe: 24 hours
| Intervention | minutes (Mean) |
|---|---|
| Placebo | 53.5 |
| Modafinil | 61.0 |
Postanesthesia quality recovery scale (PQRS). Component and aggregate scoring on the scale. Measures physiology, nociceptive, emotional activities of daily living cognitive and overall patient perspective. The scale is dimensionless and the aggregate of all individually tested dimensions is scaled from 17-65. A higher value implies improved postanesthesia recovery. Mean difference was assessed in each patient and aggregated thus patients with no difference between pre- and post-operative scores were zeroed (received a zero score if the difference was zero). A negative value was associated with worse outcome. (NCT02494102)
Timeframe: baseline and 6 hours after surgery
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -5.67 |
| Modafinil | -8.91 |
(NCT00626210)
Timeframe: 1 month
| Intervention | hours (Median) |
|---|---|
| Modafinil | 9.5 |
43 reviews available for modafinil and Gelineau Syndrome
| Article | Year |
|---|---|
Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline.
Topics: Adult; Child; Disorders of Excessive Somnolence; Humans; Idiopathic Hypersomnia; Modafinil; Narcolep | 2021 |
Precision Medicine for Idiopathic Hypersomnia.
Topics: Clarithromycin; Disorders of Excessive Somnolence; Female; Humans; Idiopathic Hypersomnia; Modafinil | 2022 |
Update on the treatment of idiopathic hypersomnia: Progress, challenges, and expert opinion.
Topics: Disorders of Excessive Somnolence; Expert Testimony; Humans; Idiopathic Hypersomnia; Modafinil; Narc | 2023 |
Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects.
Topics: Anxiety; Diarrhea; Drug Eruptions; Drug Interactions; Erythema Multiforme; Forensic Sciences; Headac | 2020 |
Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications.
Topics: Adult; Cataplexy; Humans; Methylphenidate; Modafinil; Narcolepsy; Sodium Oxybate | 2020 |
Pharmacologic Management of Excessive Daytime Sleepiness.
Topics: Central Nervous System Stimulants; Disorders of Excessive Somnolence; Humans; Idiopathic Hypersomnia | 2020 |
Evaluating pitolisant as a narcolepsy treatment option.
Topics: Animals; Cataplexy; Humans; Modafinil; Narcolepsy; Piperidines; Sleep; Sodium Oxybate; Treatment Out | 2021 |
A practical guide to the pharmacological and behavioral therapy of Narcolepsy.
Topics: Behavior Therapy; Carbamates; Counseling; Humans; Modafinil; Narcolepsy; Phenylalanine; Piperidines; | 2021 |
European guideline and expert statements on the management of narcolepsy in adults and children.
Topics: Adult; Cataplexy; Child; Humans; Modafinil; Narcolepsy; Sleep; Sodium Oxybate | 2021 |
European guideline and expert statements on the management of narcolepsy in adults and children.
Topics: Adult; Cataplexy; Child; Humans; Modafinil; Narcolepsy; Sleep; Sodium Oxybate | 2021 |
Pharmacological management of narcolepsy with and without cataplexy.
Topics: Adult; Benzhydryl Compounds; Cataplexy; Drug Therapy, Combination; Humans; Modafinil; Narcolepsy; Ne | 2017 |
Multiple treatment comparison in narcolepsy: a network meta-analysis.
Topics: Adult; Cataplexy; Humans; Modafinil; Narcolepsy; Network Meta-Analysis; Odds Ratio; Piperidines; Ris | 2018 |
Neurobiological and immunogenetic aspects of narcolepsy: Implications for pharmacotherapy.
Topics: Adjuvants, Anesthesia; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cataplexy; Central N | 2019 |
Idiopathic hypersomnia.
Topics: Benzhydryl Compounds; Diagnosis, Differential; Humans; Idiopathic Hypersomnia; Modafinil; Narcolepsy | 2016 |
A Critical Review of Properties of Modafinil and Analytical, Bioanalytical Methods for its Determination.
Topics: Benzhydryl Compounds; Chromatography, Gas; Chromatography, Liquid; Drug Compounding; Electrophoresis | 2016 |
Narcolepsy.
Topics: Adjuvants, Anesthesia; Benzhydryl Compounds; Biomarkers; Cataplexy; Genetic Predisposition to Diseas | 2017 |
Armodafinil for excessive daytime sleepiness.
Topics: Animals; Benzhydryl Compounds; Central Nervous System Stimulants; Humans; Modafinil; Narcolepsy; Sle | 2008 |
Stay awake! Understanding, diagnosing, and successfully managing narcolepsy.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Female; Humans; Male; Modafinil; Narcolepsy | 2007 |
Approved and investigational uses of modafinil : an evidence-based review.
Topics: Benzhydryl Compounds; Drug Approval; Evidence-Based Medicine; Humans; Modafinil; Narcolepsy; Randomi | 2008 |
[Falling sleep inopportunely: treatment of narcolepsy].
Topics: Adolescent; Adult; Amphetamines; Antidepressive Agents; Benzhydryl Compounds; Central Nervous System | 2008 |
Armodafinil.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Clinical Trials as Topic; Humans; Modafinil | 2009 |
Neuroimaging of narcolepsy.
Topics: Benzhydryl Compounds; Brain; Brain Mapping; Central Nervous System Stimulants; Diagnostic Imaging; H | 2009 |
Narcolepsy: clinical decision making for the primary care physician.
Topics: Benzhydryl Compounds; Biomarkers; Cataplexy; Central Nervous System Stimulants; Decision Making; Dia | 2009 |
Expert opinion on pharmacotherapy of narcolepsy.
Topics: Antidepressive Agents, Tricyclic; Benzhydryl Compounds; Caffeine; Central Nervous System Stimulants; | 2010 |
Modafinil for narcolepsy: systematic review and meta-analysis.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Female; Humans; Male; Middle Aged; Modafinil; Narcole | 2010 |
[Modafinil in psychiatric disorders: the promising state reconsidered].
Topics: Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Central Nervous System Stimulan | 2010 |
Cognitive evoked potentials in narcolepsy: a review of the literature.
Topics: Animals; Benzhydryl Compounds; Brain; Brain Mapping; Cognition; Databases, Factual; Electroencephalo | 2011 |
[Diagnostic and therapeutic update in narcolepsy].
Topics: Adolescent; Adult; Age of Onset; Animals; Autoimmune Diseases; Benzhydryl Compounds; Cataplexy; Chil | 2012 |
Clinical pharmacokinetic profile of modafinil.
Topics: Aged; Benzhydryl Compounds; Biological Availability; Central Nervous System Stimulants; Drug Interac | 2003 |
[Modafinil: pharmacology and therapeutic perspectives].
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Clinical Trials as Topic; Fatigue; Humans; | 2003 |
Managing excessive daytime sleepiness in adults.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Dextroamphetamine; Disorders of Exce | 2004 |
An update on the pharmacotherapy of excessive daytime sleepiness and cataplexy.
Topics: Animals; Antidepressive Agents; Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants; | 2004 |
Pharmacotherapy for excessive daytime sleepiness.
Topics: Amphetamines; Benzhydryl Compounds; Biological Availability; Cataplexy; Central Nervous System Stimu | 2004 |
What keeps us awake: the neuropharmacology of stimulants and wakefulness-promoting medications.
Topics: Amphetamine; Benzhydryl Compounds; Brain; Central Nervous System Stimulants; Cocaine; Dopamine Uptak | 2004 |
Conditions of primary excessive daytime sleepiness.
Topics: Automobile Driving; Benzhydryl Compounds; Central Nervous System; Central Nervous System Stimulants; | 2005 |
Molecular genetics and treatment of narcolepsy.
Topics: Animals; Antidepressive Agents, Tricyclic; Benzhydryl Compounds; Catechol O-Methyltransferase; Centr | 2006 |
Therapeutic advances in narcolepsy.
Topics: Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants; Humans; Immunotherapy; Methylphe | 2007 |
[Sleep and wakefulness drugs and their indications].
Topics: Benzhydryl Compounds; Benzodiazepines; Central Nervous System Stimulants; Humans; Hypnotics and Seda | 2007 |
Modafinil in the treatment of excessive daytime sleepiness.
Topics: Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Central Nervous System Stimulan | 2007 |
Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin.
Topics: Antidepressive Agents, Tricyclic; Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants | 2007 |
Treatment of narcolepsy and other hypersomnias of central origin.
Topics: Antidepressive Agents, Tricyclic; Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants | 2007 |
Armodafinil: a new treatment for excessive sleepiness.
Topics: Animals; Benzhydryl Compounds; Central Nervous System Stimulants; Drug and Narcotic Control; Drugs, | 2008 |
Pediatric narcolepsy.
Topics: Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants; Child; Dextroamphetamine; Ghreli | 2008 |
44 trials available for modafinil and Gelineau Syndrome
| Article | Year |
|---|---|
Incidence and duration of common, early-onset adverse events occurring during 2 randomized, placebo-controlled, phase 3 studies of sodium oxybate in participants with narcolepsy.
Topics: Adult; Disorders of Excessive Somnolence; Double-Blind Method; Humans; Incidence; Modafinil; Narcole | 2020 |
Incidence and duration of common, early-onset adverse events occurring during 2 randomized, placebo-controlled, phase 3 studies of sodium oxybate in participants with narcolepsy.
Topics: Adult; Disorders of Excessive Somnolence; Double-Blind Method; Humans; Incidence; Modafinil; Narcole | 2020 |
Incidence and duration of common, early-onset adverse events occurring during 2 randomized, placebo-controlled, phase 3 studies of sodium oxybate in participants with narcolepsy.
Topics: Adult; Disorders of Excessive Somnolence; Double-Blind Method; Humans; Incidence; Modafinil; Narcole | 2020 |
Incidence and duration of common, early-onset adverse events occurring during 2 randomized, placebo-controlled, phase 3 studies of sodium oxybate in participants with narcolepsy.
Topics: Adult; Disorders of Excessive Somnolence; Double-Blind Method; Humans; Incidence; Modafinil; Narcole | 2020 |
Effect of sodium oxybate, modafinil, and their combination on disrupted nighttime sleep in narcolepsy.
Topics: Adult; Benzhydryl Compounds; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Modafinil | 2017 |
Maintenance of Wakefulness Test, real and simulated driving in patients with narcolepsy/hypersomnia.
Topics: Adult; Automobile Driving; Computer Simulation; Cross-Over Studies; Double-Blind Method; Humans; Idi | 2019 |
Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial.
Topics: Adult; Benzhydryl Compounds; Double-Blind Method; Female; Histamine Agonists; Humans; Male; Middle A | 2013 |
Modafinil improves real driving performance in patients with hypersomnia: a randomized double-blind placebo-controlled crossover clinical trial.
Topics: Adolescent; Adult; Aged; Automobile Driving; Benzhydryl Compounds; Cross-Over Studies; Double-Blind | 2014 |
Comparing Treatment Effect Measurements in Narcolepsy: The Sustained Attention to Response Task, Epworth Sleepiness Scale and Maintenance of Wakefulness Test.
Topics: Adult; Attention; Benzhydryl Compounds; Cataplexy; Double-Blind Method; Female; Humans; Male; Modafi | 2015 |
Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy.
Topics: Adjuvants, Anesthesia; Adult; Benzhydryl Compounds; Cataplexy; Drug Therapy, Combination; Female; Hu | 2016 |
Modafinil improves information processing speed and increases energetic resources for orientation of attention in narcoleptics: double-blind, placebo-controlled ERP studies with low-resolution brain electromagnetic tomography (LORETA).
Topics: Adult; Attention; Benzhydryl Compounds; Central Nervous System Stimulants; Cognition; Double-Blind M | 2009 |
Narcolepsy: action of two gamma-aminobutyric acid type B agonists, baclofen and sodium oxybate.
Topics: Adolescent; Baclofen; Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants; Female; Fo | 2009 |
The nightly administration of sodium oxybate results in significant reduction in the nocturnal sleep disruption of patients with narcolepsy.
Topics: Adjuvants, Anesthesia; Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Drug Therapy, | 2009 |
A safety trial of sodium oxybate in patients with obstructive sleep apnea: Acute effects on sleep-disordered breathing.
Topics: Adjuvants, Anesthesia; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Comorbi | 2010 |
Treatment of sleep disorders after traumatic brain injury.
Topics: Adult; Benzhydryl Compounds; Benzothiazoles; Brain Injuries; Central Nervous System Stimulants; Diso | 2009 |
Efficacy of modafinil in 10 Taiwanese patients with narcolepsy: findings using the Multiple Sleep Latency Test and Epworth Sleepiness Scale.
Topics: Adolescent; Benzhydryl Compounds; Child; Female; Follow-Up Studies; Humans; Male; Modafinil; Narcole | 2010 |
Modafinil reverses hypoexcitability of the motor cortex in narcoleptic patients: a TMS study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Evoked Potentia | 2010 |
The effect of modafinil on cortical excitability in patients with narcolepsy: a randomized, placebo-controlled, crossover study.
Topics: Adult; Benzhydryl Compounds; Case-Control Studies; Central Nervous System Stimulants; Cross-Over Stu | 2010 |
Tolerability and efficacy of armodafinil in naïve patients with excessive sleepiness associated with obstructive sleep apnea, shift work disorder, or narcolepsy: a 12-month, open-label, flexible-dose study with an extension period.
Topics: Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Female; Follow-Up Studies; Hea | 2010 |
The long-term tolerability and efficacy of armodafinil in patients with excessive sleepiness associated with treated obstructive sleep apnea, shift work disorder, or narcolepsy: an open-label extension study.
Topics: Adult; Benzhydryl Compounds; Blood Pressure; Central Nervous System Stimulants; Double-Blind Method; | 2010 |
Modafinil ameliorates excessive daytime sleepiness after traumatic brain injury.
Topics: Adult; Aged; Benzhydryl Compounds; Brain Injuries; Disorders of Excessive Somnolence; Double-Blind M | 2010 |
Initiating treatment with modafinil for control of excessive daytime sleepiness in patients switching from methylphenidate: an open-label safety study assessing three strategies.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Drug Administratio | 2003 |
Efficacy and safety of modafinil for improving daytime wakefulness in patients treated previously with psychostimulants.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Dextroamphetamine; | 2003 |
Effect of modafinil on fatigue, mood, and health-related quality of life in patients with narcolepsy.
Topics: Adolescent; Adult; Affect; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Dose-Respo | 2004 |
EEG-mapping differences between narcolepsy patients and controls and subsequent double-blind, placebo-controlled studies with modafinil.
Topics: Adult; Benzhydryl Compounds; Brain Mapping; Case-Control Studies; Double-Blind Method; Electroenceph | 2005 |
EEG-tomographic studies with LORETA on vigilance differences between narcolepsy patients and controls and subsequent double-blind, placebo-controlled studies with modafinil.
Topics: Adult; Arousal; Benzhydryl Compounds; Brain Mapping; Double-Blind Method; Drug Administration Schedu | 2004 |
Dose effects of modafinil in sustaining wakefulness in narcolepsy patients with residual evening sleepiness.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Demography; Dose-Response Relationship, Drug; Double- | 2005 |
The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Metho | 2006 |
Sodium oxybate improves excessive daytime sleepiness in narcolepsy.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Disorders of Excessive Somnolence; D | 2006 |
Low-resolution brain electromagnetic tomography (LORETA) identifies brain regions linked to psychometric performance under modafinil in narcolepsy.
Topics: Adult; Affect; Arousal; Benzhydryl Compounds; Brain Mapping; Central Nervous System Stimulants; Cogn | 2007 |
Modafinil-induced hippocampal activation in narcolepsy.
Topics: Adolescent; Adult; Benzhydryl Compounds; Brain Mapping; Brain Stem; Central Nervous System Stimulant | 2007 |
Cerebral blood flow changes in man by wake-promoting drug, modafinil: a randomized double blind study.
Topics: Acoustic Stimulation; Adult; Benzhydryl Compounds; Brain; Central Nervous System Stimulants; Cerebro | 2008 |
An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients.
Topics: Animals; Benzhydryl Compounds; Central Nervous System Stimulants; Disease Models, Animal; Female; Hi | 2008 |
Effects of modafinil on symptomatology of human narcolepsy.
Topics: Adult; Analysis of Variance; Arousal; Benzhydryl Compounds; Blood Pressure; Body Temperature; Centra | 1993 |
Use of modafinil in the treatment of narcolepsy: a long term follow-up study.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Child; Female; Fol | 1996 |
Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Circadian Rhythm; Cross-Over Studies | 1997 |
Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Dose-Response Rela | 1998 |
HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants; Female; | 1997 |
Effect of modafinil on plasma melatonin, cortisol and growth hormone rhythms, rectal temperature and performance in healthy subjects during a 36 h sleep deprivation.
Topics: Adult; Benzhydryl Compounds; Body Temperature; Central Nervous System Stimulants; Health Status; Hum | 1998 |
Sleep latency on the maintenance of wakefulness test (MWT) for 530 patients with narcolepsy while free of psychoactive drugs.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Data Interpretatio | 1998 |
Functional magnetic resonance imaging neuroactivation studies in normal subjects and subjects with the narcoleptic syndrome. Actions of modafinil.
Topics: Acoustic Stimulation; Adolescent; Adult; Arousal; Benzhydryl Compounds; Brain; Central Nervous Syste | 1999 |
Visual P300 latency predicts treatment response to modafinil in patients with narcolepsy.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Metho | 1999 |
Health-related quality of life effects of modafinil for treatment of narcolepsy.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Cost of Illness; Double-Blind Method | 1999 |
Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Double-Blind Method; Female; Humans; Male; Middle Age | 2000 |
Problems associated with switch to modafinil - a novel alerting agent in narcolepsy.
Topics: Adult; Aged; Amphetamines; Benzhydryl Compounds; Central Nervous System Stimulants; Drug Combination | 2000 |
Modafinil for narcolepsy.
Topics: Adult; Aged; Ambulatory Care; Benzhydryl Compounds; Central Nervous System Stimulants; Female; Human | 2001 |
Relative efficacy of drugs for the treatment of sleepiness in narcolepsy.
Topics: Adult; Arousal; Benzhydryl Compounds; Central Nervous System Stimulants; Codeine; Dextroamphetamine; | 1991 |
92 other studies available for modafinil and Gelineau Syndrome
| Article | Year |
|---|---|
Narcolepsy treatment in Sweden: An observational study.
Topics: Antidepressive Agents; Female; Humans; Male; Modafinil; Narcolepsy; Sodium Oxybate; Sweden | 2022 |
Infant Exposure to Armodafinil Through Human Milk Following Maternal Use of Modafinil.
Topics: Adult; Benzhydryl Compounds; Breast Feeding; Female; Humans; Infant; Milk, Human; Modafinil; Narcole | 2023 |
Infant Exposure to Armodafinil Through Human Milk Following Maternal Use of Modafinil.
Topics: Adult; Benzhydryl Compounds; Breast Feeding; Female; Humans; Infant; Milk, Human; Modafinil; Narcole | 2023 |
Infant Exposure to Armodafinil Through Human Milk Following Maternal Use of Modafinil.
Topics: Adult; Benzhydryl Compounds; Breast Feeding; Female; Humans; Infant; Milk, Human; Modafinil; Narcole | 2023 |
Infant Exposure to Armodafinil Through Human Milk Following Maternal Use of Modafinil.
Topics: Adult; Benzhydryl Compounds; Breast Feeding; Female; Humans; Infant; Milk, Human; Modafinil; Narcole | 2023 |
Infant Exposure to Armodafinil Through Human Milk Following Maternal Use of Modafinil.
Topics: Adult; Benzhydryl Compounds; Breast Feeding; Female; Humans; Infant; Milk, Human; Modafinil; Narcole | 2023 |
Infant Exposure to Armodafinil Through Human Milk Following Maternal Use of Modafinil.
Topics: Adult; Benzhydryl Compounds; Breast Feeding; Female; Humans; Infant; Milk, Human; Modafinil; Narcole | 2023 |
Infant Exposure to Armodafinil Through Human Milk Following Maternal Use of Modafinil.
Topics: Adult; Benzhydryl Compounds; Breast Feeding; Female; Humans; Infant; Milk, Human; Modafinil; Narcole | 2023 |
Infant Exposure to Armodafinil Through Human Milk Following Maternal Use of Modafinil.
Topics: Adult; Benzhydryl Compounds; Breast Feeding; Female; Humans; Infant; Milk, Human; Modafinil; Narcole | 2023 |
Infant Exposure to Armodafinil Through Human Milk Following Maternal Use of Modafinil.
Topics: Adult; Benzhydryl Compounds; Breast Feeding; Female; Humans; Infant; Milk, Human; Modafinil; Narcole | 2023 |
Comparison of Solriamfetol and Modafinil on Arousal and Anxiety-Related Behaviors in Narcoleptic Mice.
Topics: Animals; Anxiety; Arousal; Disorders of Excessive Somnolence; Mice; Modafinil; Narcolepsy | 2023 |
[Potential teratogenicity of modafinil - Conflicting evidence, need for research].
Topics: Central Nervous System Stimulants; Disorders of Excessive Somnolence; Female; Humans; Idiopathic Hyp | 2023 |
Pitolisant-supported bridging during drug holidays to deal with tolerance to modafinil in patients with narcolepsy.
Topics: Benzhydryl Compounds; Disorders of Excessive Somnolence; Humans; Modafinil; Narcolepsy; Piperidines; | 2023 |
Somnolence Preceded the Development of a Subthalamic Lesion in Neuromyelitis Optica Spectrum Disorder.
Topics: Aged; Central Nervous System Stimulants; Female; Humans; Japan; Magnetic Resonance Imaging; Methylph | 2020 |
Pregnancy and Fetal Outcomes Following Exposure to Modafinil and Armodafinil During Pregnancy.
Topics: Abnormalities, Drug-Induced; Female; Humans; Modafinil; Narcolepsy; Pregnancy; Registries; United St | 2021 |
Narcolepsy management in Australia: time to wake up.
Topics: Australia; Dextroamphetamine; Drug Costs; Health Expenditures; Health Services Accessibility; Humans | 2021 |
Pitolisant, a wake-promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; Amphetamine; Animals; Carbamates; Corp | 2021 |
Narcolepsy with cataplexy and pregnancy: a case-control study.
Topics: Adult; Breast Feeding; Case-Control Studies; Cataplexy; Central Nervous System Stimulants; Cesarean | 2018 |
Narcolepsy-cataplexy and psychosis: a case study.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compound | 2017 |
Increased interferon-mediated immunity following in vitro and in vivo Modafinil treatment on peripheral immune cells.
Topics: Animals; Benzhydryl Compounds; Cell Death; Cell Proliferation; Cells, Cultured; Dose-Response Relati | 2018 |
Effectiveness and side-effect profile of stimulant therapy as monotherapy and in combination in the central hypersomnias in clinical practice.
Topics: Adult; Central Nervous System Stimulants; Drug Therapy, Combination; Female; Follow-Up Studies; Head | 2018 |
Michel Jouvet as a clinical neurophysiologist and neurologist.
Topics: Animals; Cats; Central Nervous System Stimulants; Clinical Competence; Disorders of Excessive Somnol | 2018 |
The unfinished journey with modafinil and discovery of a novel population of modafinil-immunoreactive neurons.
Topics: Animals; Brain; Cats; Central Nervous System Stimulants; France; Humans; Immunohistochemistry; Mice, | 2018 |
Modafinil: its discovery, the early European and North American experience in the treatment of narcolepsy and idiopathic hypersomnia, and its subsequent use in other medical conditions.
Topics: Adrenergic alpha-Agonists; Animals; Central Nervous System Stimulants; Clinical Trials as Topic; Dis | 2018 |
The Comorbidity of Focal Epilepsy and Narcolepsy Type 1 - Two Case Reports.
Topics: Adult; Amnesia; Anticonvulsants; Behavior; Central Nervous System Stimulants; Electroencephalography | 2018 |
Antidepressants for the treatment of narcolepsy: A prospective study of 148 patients in northern China.
Topics: Adult; Antidepressive Agents; Female; Humans; Male; Middle Aged; Modafinil; Narcolepsy; Prospective | 2019 |
Safety profile of modafinil across a range of prescribing indications, including off-label use, in a primary care setting in England: results of a modified prescription-event monitoring study.
Topics: Adolescent; Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Child; Cohort Studies; D | 2013 |
A need for new treatments in narcolepsy.
Topics: Benzhydryl Compounds; Female; Histamine Agonists; Humans; Male; Modafinil; Narcolepsy; Piperidines; | 2013 |
Status cataplecticus as initial presentation of late onset narcolepsy.
Topics: Benzhydryl Compounds; Cataplexy; Clomipramine; Diagnosis, Differential; Electroencephalography; Foll | 2014 |
Prader-Willi syndrome, excessive daytime sleepiness, and narcoleptic symptoms: a case report.
Topics: Benzhydryl Compounds; Child; Disorders of Excessive Somnolence; Female; Humans; Modafinil; Narcoleps | 2014 |
Attention-Deficit/Hyperactivity Disorder (ADHD) Symptoms in Pediatric Narcolepsy: A Cross-Sectional Study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Case-Control Studie | 2015 |
Sleep-stage sequencing of sleep-onset REM periods in MSLT predicts treatment response in patients with narcolepsy.
Topics: Adult; Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants; Female; Humans; Male; Mod | 2016 |
Impact of Astroglial Connexins on Modafinil Pharmacological Properties.
Topics: Animals; Astrocytes; Benzhydryl Compounds; Connexin 30; Connexin 43; Connexins; Disease Models, Anim | 2016 |
Wake-promoting effects of ONO-4127Na, a prostaglandin DP1 receptor antagonist, in hypocretin/orexin deficient narcoleptic mice.
Topics: Animals; Ataxin-3; Benzhydryl Compounds; Body Temperature; Disease Models, Animal; Electroencephalog | 2016 |
Day case general anaesthesia in a patient with narcolepsy.
Topics: Adult; Ambulatory Surgical Procedures; Anesthesia, General; Anesthetics, Inhalation; Benzhydryl Comp | 2008 |
Effect of modafinil on cerebral blood flow in narcolepsy patients.
Topics: Adolescent; Adult; Benzhydryl Compounds; Brain; Central Nervous System Stimulants; Cerebrovascular C | 2008 |
Modafinil-induced psychosis.
Topics: Adult; Benzhydryl Compounds; Humans; Male; Modafinil; Narcolepsy; Psychotic Disorders | 2008 |
Gaps that wake you up.
Topics: Animals; Arousal; Benzhydryl Compounds; Central Nervous System Stimulants; Evoked Potentials, Audito | 2008 |
Conception, pregnancy, delivery, and breastfeeding in a narcoleptic patient with cataplexy.
Topics: Adult; Benzhydryl Compounds; Breast Feeding; Cataplexy; Central Nervous System Stimulants; Contraind | 2008 |
[Disorders in the regulation of alertness. Drowsy white rock climbing and wide awake at night].
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Diagnosis, Differential; Electroencephalogr | 2008 |
A multi-drug intoxication fatality involving Xyrem (GHB).
Topics: Amines; Benzhydryl Compounds; Carisoprodol; Central Nervous System Depressants; Cetirizine; Cyclohex | 2009 |
Psychological health in central hypersomnias: the French Harmony study.
Topics: Adult; Antidepressive Agents; Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants; Co | 2009 |
Differential effects of acute and repeat dosing with the H3 antagonist GSK189254 on the sleep-wake cycle and narcoleptic episodes in Ox-/- mice.
Topics: Animals; Autoradiography; Benzazepines; Benzhydryl Compounds; Brain; Dose-Response Relationship, Dru | 2009 |
Specificity of direct transition from wake to REM sleep in orexin/ataxin-3 transgenic narcoleptic mice.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Tricyclic; Ataxin-3; Benzhydryl Compounds; Cen | 2009 |
Narcolepsy--master of disguise: evidence-based recommendations for management.
Topics: Adjuvants, Anesthesia; Attention Deficit and Disruptive Behavior Disorders; Benzhydryl Compounds; Ca | 2009 |
Hallucinations associated with modafinil treatment for narcolepsy.
Topics: Adaptation, Psychological; Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Drug Admi | 2009 |
Narcolepsy and psychotic states--a case report.
Topics: Antipsychotic Agents; Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants; Comorbidit | 2009 |
Rapid occurrence of depression following addition of sodium oxybate to modafinil.
Topics: Adjuvants, Anesthesia; Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Depression; D | 2010 |
Pathological gambling associated with modafinil.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Clomipramine; Disruptive, Impulse Co | 2010 |
National narcolepsy survey.
Topics: Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants; Health Surveys; Humans; Intracel | 2010 |
Effects of paraxanthine and caffeine on sleep, locomotor activity, and body temperature in orexin/ataxin-3 transgenic narcoleptic mice.
Topics: Animals; Ataxin-3; Benzhydryl Compounds; Body Temperature; Caffeine; Central Nervous System Stimulan | 2010 |
Neuraxial anaesthesia for caesarean section in a patient with narcolepsy and cataplexy.
Topics: Adult; Anesthesia, Epidural; Anesthesia, Obstetrical; Antidepressive Agents, Second-Generation; Benz | 2010 |
Clinical and therapeutic aspects of childhood narcolepsy-cataplexy: a retrospective study of 51 children.
Topics: Adjuvants, Anesthesia; Adolescent; Age Distribution; Age of Onset; Antidepressive Agents, Second-Gen | 2010 |
Anesthetic management of a patient with narcolepsy.
Topics: Anesthesia; Anesthetics, Inhalation; Anesthetics, Intravenous; Anti-Inflammatory Agents, Non-Steroid | 2011 |
Severe mania complicating treatment of narcolepsy with cataplexy.
Topics: Antidepressive Agents, Second-Generation; Benzhydryl Compounds; Bipolar Disorder; Central Nervous Sy | 2011 |
Benefit and risk of modafinil in idiopathic hypersomnia vs. narcolepsy with cataplexy.
Topics: Adult; Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants; Cohort Studies; Databases | 2011 |
Narcolepsy, idiopathic hypersomnolence and related conditions.
Topics: Antidepressive Agents, Tricyclic; Benzhydryl Compounds; Catalepsy; Central Nervous System Stimulants | 2011 |
Assessment of brain activity during memory encoding in a narcolepsy patient on and off modafinil using normative fMRI data.
Topics: Adult; Behavior; Benzhydryl Compounds; Brain; Brain Mapping; Central Nervous System Stimulants; Fema | 2012 |
Clinical experience suggests that modafinil is an effective and safe treatment for paediatric narcolepsy.
Topics: Adolescent; Benzhydryl Compounds; Central Nervous System Stimulants; Child; Child, Preschool; Female | 2012 |
Childhood narcolepsy- a rare disorder.
Topics: Benzhydryl Compounds; Child; Diagnosis, Differential; Female; Humans; Modafinil; Narcolepsy; Polysom | 2013 |
By the way, doctor. What can you tell me about the new drug Provigil? I've read that it helps people stay awake without feeling jittery. For those of us who work a lot of overtime, it sounds like a dream come true.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Drug Labeling; Humans; Modafinil; Narcoleps | 2003 |
Cataplexy worsened by modafinil.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Humans; Male; Middle Aged; Modafinil; Narco | 2003 |
Narcolepsy drug could be approved for wider use.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Drug Approval; Humans; Modafinil; Narcoleps | 2003 |
Modafinil in the treatment of excessive daytime sleepiness in children.
Topics: Adolescent; Benzhydryl Compounds; Central Nervous System Stimulants; Child; Child, Preschool; Circad | 2003 |
Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin-deficiency narcolepsy.
Topics: Acute Disease; Benzhydryl Compounds; Carrier Proteins; Central Nervous System Stimulants; Child; Cyc | 2003 |
Concomitant use of modafinil and tranylcypromine in a patient with narcolepsy: a case report.
Topics: Benzhydryl Compounds; Blood Pressure; Cataplexy; Central Nervous System Stimulants; Comorbidity; Dep | 2004 |
Modafinil more effectively induces wakefulness in orexin-null mice than in wild-type littermates.
Topics: Animals; Attention; Benzhydryl Compounds; Brain; Central Nervous System Stimulants; Dose-Response Re | 2005 |
Fragmentation of sleep-wake cycle secondary to narcolepsy and Cheyne-Stokes respiration.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Cheyne-Stokes Respiration; Humans; Male; Mi | 2005 |
The month-of-birth pattern in narcolepsy is moderated by cataplexy severity and may be independent of HLA-DQB1*0602.
Topics: Adult; Age of Onset; Aged; Benzhydryl Compounds; Brain; Cataplexy; Central Nervous System Stimulants | 2004 |
Modafinil in sports: ethical considerations.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Doping in Sports; Female; Humans; Modafinil | 2005 |
What is modafinil?
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Humans; Modafinil; Narcolepsy; Sleep Stages | 2005 |
Mania in a boy treated with modafinil for narcolepsy.
Topics: Adolescent; Benzhydryl Compounds; Bipolar Disorder; Central Nervous System Stimulants; Humans; Male; | 2005 |
Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil.
Topics: Adrenergic Agents; Animals; Benzhydryl Compounds; Benzylamines; Brain; Central Nervous System Stimul | 2005 |
Alertness drug arouses fears about 'lifestyle' misuse.
Topics: Alzheimer Disease; Animals; Attention; Benzhydryl Compounds; Clinical Trials as Topic; Cognition; Gl | 2005 |
Narcolepsy-cataplexy associated with precocious puberty.
Topics: Aspartic Acid; Benzhydryl Compounds; Cataplexy; Child; Creatine; Cyclohexanols; Disorders of Excessi | 2006 |
EFNS guidelines on management of narcolepsy.
Topics: Advisory Committees; Antidepressive Agents; Benzhydryl Compounds; Catalepsy; Central Nervous System | 2006 |
[Narcolepsy and anesthesia].
Topics: Analgesia, Epidural; Anesthesia, Intravenous; Antiemetics; Benzhydryl Compounds; Chemical and Drug I | 2007 |
Narcolepsy: treatment issues.
Topics: Antidepressive Agents; Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants; Circadian | 2007 |
[Effect of modafinil in narcoleptic patients. Electrophysiologic and psychometric studies].
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Electrophysiology; Female; Humans; M | 1995 |
Modafinil in diurnal sleepiness. A study of 123 patients.
Topics: Adolescent; Adult; Age of Onset; Aged; Benzhydryl Compounds; Cataplexy; Central Nervous System Stimu | 1994 |
Modafinil binds to the dopamine uptake carrier site with low affinity.
Topics: Animals; Arousal; Benzhydryl Compounds; Binding, Competitive; Brain; Central Nervous System Stimulan | 1994 |
[The effects of modafinil (300mg) on sleep, sleepiness and arousal in narcoleptic patients].
Topics: Adolescent; Adult; Age Factors; Arousal; Benzhydryl Compounds; Central Nervous System Stimulants; Fe | 1993 |
Fibrositis syndrome and narcolepsy.
Topics: Aged; Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants; Female; Fibromyalgia; Huma | 1993 |
Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs.
Topics: Amphetamine; Animals; Behavior, Animal; Benzhydryl Compounds; Cataplexy; Central Nervous System Stim | 1995 |
Narcolepsy researchers barking up the right tree.
Topics: Animals; Benzhydryl Compounds; Central Nervous System Stimulants; Dog Diseases; Dogs; Drugs, Investi | 1996 |
[Gélineau syndrome in a patient with renal transplantation. Evidence of cyclosporine-modafinil interaction].
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Cyclosporine; Drug Interactions; Fem | 1997 |
Modafinil: an antinarcoleptic drug with a different neurochemical profile to d-amphetamine and dopamine uptake blockers.
Topics: Animals; Benzhydryl Compounds; Biogenic Amines; Central Nervous System Stimulants; Dextroamphetamine | 1997 |
Modafinil for narcolepsy.
Topics: Aryl Hydrocarbon Hydroxylases; Benzhydryl Compounds; Central Nervous System Stimulants; Controlled C | 1999 |
Peripheral vasculopathy and nephropathy in association with phentermine.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Female; Humans; Kidney Diseases; Middle Age | 1999 |
Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation.
Topics: Age of Onset; Animals; Benzhydryl Compounds; Carrier Proteins; Disease Models, Animal; Dog Diseases; | 1999 |
[Modafinil in narcolepsy. A new therapeutic principle proves successful].
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Humans; Modafinil; Narcolepsy | 2000 |
Modafinil approved for narcolepsy.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Humans; Modafinil; Narcolepsy | 1999 |
[Modafinil (Midiodal): wakefulness stimulant in narcoleptic patients].
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Dose-Response Relationship, Drug; Drug Admi | 2000 |
Modafinil treatment of pramipexole-associated somnolence.
Topics: Adult; Antiparkinson Agents; Benzhydryl Compounds; Benzothiazoles; Central Nervous System Stimulants | 2000 |
Dopaminergic role in stimulant-induced wakefulness.
Topics: Amphetamine; Animals; Benzhydryl Compounds; Caffeine; Carrier Proteins; Caudate Nucleus; Central Ner | 2001 |
Dopaminergic role in stimulant-induced wakefulness.
Topics: Amphetamine; Animals; Benzhydryl Compounds; Caffeine; Carrier Proteins; Caudate Nucleus; Central Ner | 2001 |
Dopaminergic role in stimulant-induced wakefulness.
Topics: Amphetamine; Animals; Benzhydryl Compounds; Caffeine; Carrier Proteins; Caudate Nucleus; Central Ner | 2001 |
Dopaminergic role in stimulant-induced wakefulness.
Topics: Amphetamine; Animals; Benzhydryl Compounds; Caffeine; Carrier Proteins; Caudate Nucleus; Central Ner | 2001 |
Sleepless in America.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Humans; Modafinil; Narcolepsy; United State | 2001 |
Is psychosis exacerbated by modafinil?
Topics: Benzhydryl Compounds; Clozapine; Drug Interactions; Drug Therapy, Combination; Female; Humans; Middl | 2002 |
Sexual dimorphism of the catechol-O-methyltransferase gene in narcolepsy is associated with response to modafinil.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Catechol O-Methyltransferase; Cent | 2002 |
Secondary narcolepsy in children with brain tumors.
Topics: Adolescent; Benzhydryl Compounds; Brain Neoplasms; Central Nervous System Stimulants; Child; Child, | 2002 |
Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil.
Topics: Adrenergic alpha-Agonists; Adult; Benzhydryl Compounds; Disorders of Excessive Somnolence; Female; H | 1988 |